

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Low to high intensity computer-based cognitive training at home in supplement to standard care in AD patients: protocol design

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2021-050993 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 05-Mar-2021 |
| Complete List of Authors: | Dimachki, Samar; Université Lyon 2, Laboratoire d'Etude des Mécanismes Cognitifs Tarpin-Bernard, Franck Croisile, Bernard; Hospices Civils de Lyon Chainay, Hanna |
| Keywords: | GERIATRIC MEDICINE, Neurology < INTERNAL MEDICINE, Dementia < NEUROLOGY, REHABILITATION MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9 **Low to high intensity computer-based cognitive training at home in**
10 **supplement to standard care in AD patients: protocol design**
11
12
13
14
15
16
17

18 Samar Dimachki^{1,3}, Franck Tarpin-Bernard³, Bernard Croisile² & Hanna Chainay¹
19
20
21
22

23 ¹ Université Lyon 2, Laboratoire d'Etude des Mécanismes Cognitifs
24
25

26 ² Hôpital Neurologique, Hospices Civils de Lyon
27

28 ³ Scientific Brain Training SA
29

30 samar.dimachki@univ-lyon2.fr
31

32 f.tarpin@sbt-human.com
33

34 bernard.croisile@wanadoo.fr
35

36 hanna.chainay@univ-lyon2.fr
37
38

39 Corresponding author : Samar Dimachki
40

41 Université Lyon 2
42

43 Laboratoire d'Étude des Mécanismes Cognitifs
44

45 5 avenue Pierre Mendès France
46

47 69676 Bron, France
48

49 e-mail : samar.dimachki@univ-lyon2.fr
50
51
52
53

54 Words count: 4015
55
56
57
58
59
60

Abstract

Introduction: Recent studies on cognitive training carried out with Alzheimer's disease (AD) patients showed positive long-term lasting effects of training on cognition and activities of daily living and suggested conceiving remote computer-based programs to increase training sessions while reducing patient's travelling. The main objective of this study is to examine short- and long-term benefits of computer-based cognitive training in mild to moderate AD patients realized at home, as a complement to the training carried out in speech and language therapist (SLT) offices. The secondary purpose is to study training frequency required to obtain noticeable effects.

Methods and analysis: This is a national multi-center study, taking place in SLT offices. The AD patients follow training in one of the three conditions: once a week in SLT office only (as usual condition) and once a week in SLT office plus one or three times per week at home. The effects of training at home and its frequency will be evaluated by comparing near and far transfer observed at the three training groups.

Ethics and dissemination: The study is conducted with ethics approval of the national ethical committee CPP Sud Méditerranée III (Nr. 2019-A00458-49) and of the National Commission for Information Technology and Liberties (Nr. 919217). Written and signed informed consent is obtained from each participant. The results of the study will be disseminated in the form of oral communications or posters in international conferences (e.g., Alzheimer's Association International Conference) and published in a scientific journal in the field (e.g., Journal of Alzheimer's Disease).

Trial registration number: ClinicalTrials.gov identifier (NCT04010175).

Keywords: prodromal to moderate Alzheimer's disease, computer-based cognitive training, at home cognitive training, cognitive benefits, quality of life improvement

Strengths and limitations of the study

- ▶ This study will provide information on the short- and long-term effects of remote computer-based cognitive training in addition to regular training in SLT office for Alzheimer's patients.
- ▶ This study will shed light on the optimal cognitive training frequency to be administered.
- ▶ This study will evaluate the adherence to the computerized program at home in comparison with the trainings carried out exclusively in the SLT office, knowing that this factor is likely to be favorable to the adherence taking into account the reduction of travel and the training in a familiar environment.
- ▶ The limitation of the present study is that it will not control the familiarity of the Alzheimer's disease patients with the computer tool, nor their degree of autonomy in accomplishing the training at home on their own.

INTRODUCTION

Considering increasing occurrence of neurodegenerative disorders in the elderly, such as Alzheimer's disease (AD), and in the absence of effective drug treatment, usage of cognitive training seems to be a promising alternative in healthy and pathological aging for improving cognitive functioning [1-3] and quality of life [4-5]. For some researchers cognitive training also constitutes an added value to drug treatment, as it was observed to amplify the expression of drug effects [6].

The efficacy of cognitive training in patients with AD is still under the debate [8], especially concerning the best methodological approaches to be applied to optimize the training outcomes [9-10], including training feasibility, patient's commitment, and motivation. The computer-based cognitive training (CBCT) seems to have several advantages because it provides wide variety of well-calibrated exercises and allows for example to easily adapt their difficulty to each patient [11]. The CBCT short- and long-term benefits was first shown in healthy elderly [7,12,13], but has also been proven in patients with AD and MCI [14-18].

Several studies have highlighted the importance of some essential criteria for successful training, whatever its type [19, 15, 20]. Globally, the studies recommend early intervention with sessions between 30 minutes and 1 hour and session's frequency set at several times a week [9-10, 21]. Such a design is supposed to maintain strong commitment and motivation throughout the training, indispensable for its efficiency. However, these recommendations face some important problems that render their application difficult. First, few people are concerned about small changes in performance, the majority will only consult when symptoms become more pronounced, which prevents from early intervention suggested by several authors [21-25]. Second, patients' involvement in high frequency cognitive training protocols faces several difficulties, most importantly, frequent travels between home and speech-language pathologist's office (SPL). As the disease progresses, autonomy is compromised, and the need of a caregiver's help is a supplemental difficulty. In addition, the changing seasons lead to many health problems that hinder the training and often lead to interruptions. One way of circumventing these problems would be to propose a CBCT including some sessions at home [26,17].

The main objective of the present study is to examine the short- and long-term benefits of CBCT realized at home as a complement to in-office CBCT in mild to moderate Alzheimer's disease patients. The secondary objective is to evaluate the best frequency of the at home training. To do so, we administer computer-based cognitive training for 4 months under three conditions: (1) in SPL's office one-time per week, (2) in SPL's office one time per week plus one time at home, and (3) in SPL's office one time per week plus three times at home.

Method

1. Design

This is an experimental study with minimal risks, with 3 parallel groups, namely in SLT's office only training group (REG – regular group), in SPL's office plus one session per week at home (MFG - moderate frequency group) and in SPL's office plus three session per week at home (HFG – high frequency group). The inclusion of patients will be done for 2 years, starting from the 1st September 2019 and ending 1st September 2021. For each participant, the inclusion period is approximately 8 months. During this period, participants cannot be included in other protocols that are susceptible to influence their cognitive or emotional functions. The total duration of the study is 32 months. All inclusions and testing will be realized in SLT offices. The training will be done in SLT offices and at patients' homes (see Figure 1 for a study design).

This study obtained the authorization of the national ethical committee CPP Sud Méditerranée III (Nr. 2019-A00458-49, version 5 from 18/11/2019) and of the National Commission for Information Technology and Liberties (Nr. 919217) and was registered on clinicaltrials.gov (NCT04010175).

Insert Figure 1 here

2. Participants

This study concerns people over 60 years of age with a diagnosis of prodromal to moderate Alzheimer's disease. To recruit participants, we contacted SLTs subscribers to SBT's Happyneuron Pro digital tools through the SBT Human(s) Matter company network. They first answered a questionnaire in order to identify SLTs practicing with AD patients. These SLT received an invitation letter for participation to our study. Finally, 27 SLTs from different parts of France joined the study and become clinical investigation centers (CIS). A full list of these SLTs can be obtained from the Department of Clinical Research and Innovation of the Hospices Civils of Lyon¹. Each SLT oversees presenting the study in his or her office to patients whose profile match our inclusion criteria. The interested patients will receive the information and consent leaflets. During the next visit they will be asked if he/she wished to participate

¹ Direction de la Recherche Clinique, Hospice Civil de Lyon
3, quai des Célestins, 69229 Lyon Cedex 2

1
2
3 to the study, and if so the informed consent will be signed. Thus, the patients are included by the SLTs
4 who also sign a informed consent after the neurologist's validation, the Principal Investigator of this
5 study. Patients are informed that during the study they cannot take part in any other study that could
6 potentially have an effect on their cognitive functions.
7
8
9

10 11 **2.1 Eligibility**

12 The eligibility criteria are presented in Box 1.
13
14

15
16
17 _____
18 Insert Box 1 here
19 _____
20
21
22
23
24

25 **2.2 Withdrawal Criteria**

26 Each patient is free to withdraw from the study at any time without giving the reasons, by simply
27 informing one of the investigators. If consent is withdrawn, the data collected up to the date of
28 withdrawal will be analyzed.
29
30
31
32

33 **3. Randomization and Anonymization Method**

34 To avoid any unequal treatment of patients in the same SLT, we decided to randomize SLTs' offices to
35 different training groups, instead of randomizing patients. Thus, each office will be assigned to one of
36 training group and all patients included in this SLT office will follow the same training procedure (REG,
37 MFG or HFG). The offices will be assigned to each group in a balanced way in terms of socio-
38 demographic considerations, depending on their geographical location. It will be done by a Head of
39 Research & Development department in SBT before the study beginning. If, despite randomization, an
40 imbalance occurs within groups due to inter-individual differences such as age, gender, education and
41 disease severity, these factors would be considered as covariant in results analysis.
42
43
44
45
46
47
48

49 Each patient will receive an anonymization number composed, in order, of the number of the
50 investigating center, the inclusion number for this center and the patient's initials. The SLT will keep
51 the table of correspondence between this number and the first and last name, as well as the address
52 and telephone number for all patients included in his/her center.
53
54
55
56
57
58
59
60

4. Procedure

Our study follows a conventional protocol used to evaluate the cognitive and psychological benefits resulting from cognitive training (for a review, [42]) (see Figure 2 and Table 1 for details).

Insert Figure 2 and Table 1 here

5. Primary measures of training benefits

Our primary measures, performed by SLTs, are patient's scores on neuropsychological tests, questionnaires, and experimental tasks performed in the three time-points (T0, T1, and T2). The choice of these measures was made according to the trained cognitive functions and the cognitive (working memory, executive functions) and psychological (self-esteem, motivation, psychological state - depression/anxiety, assessment of quality of life) domains for which training benefits are expected. These evaluations enable us to first determine the baseline level of patient's cognitive capacities and his or her emotional and motivational state and second to measure the training benefit by comparing the pre-training results (T0) with those obtained immediately after the end of the training (T1) and 3 month later (T2).

5.1 Neuropsychological tests

Verbal Fluency [27]

The overall objective of the fluency test is to evaluate executive functions by accessing patient's capacity to access their lexical repertoire according to a given letter or a semantic category.

TMT A/B [28]

Trail Making Test consists of two parts. Part A measure processing speed – the patient must connect in ascending order the 25 numbers randomly distributed in circles on the A4 page. Part B measure cognitive flexibility – the patient must perform the same task as in part A while alternating between numbers and letters (i.e., 1-A-2-B-3-C, etc.).

Logical Memory [29]

Logical Memory I and II are subtests of the *MEM Wechsler IV*. Each correctly recalled detail out of 25 details per story is scored 1 point, giving the maximum raw score of 50 points for two stories. Logical

1
2
3 Memory II is a delayed condition of Logical Memory I. The test ends with recognition, in which patient
4 must answer a series of questions concerning each story.
5

6 7 *MMSE [30]*

8
9 The Mini Mental State Examination (MMSE) is a commonly used test for screening general cognitive
10 impairment. The maximum MMSE score is 30 points.
11

12 13 *Digit Span [29]*

14 Two types of span are used, forward and backward to measure respectively short-term and working
15 memory. For both span the test ends if the participant fails to repeat two consecutive series. The
16 maximum score is 48.
17
18

19 20 **5.2 Questionnaires**

21 22 23 *Geriatric Depression Scale (GDS) 30 items [31]*

24 GDS is 30 items, self-reported scale that uses "Yes/No" responses. It is used to detect the symptoms
25 of depression in older adults. Scores of 0-4 are considered normal, 5-8 indicate mild depression; 9-11
26 indicate moderate depression; and 12-15 indicate severe depression.
27
28

29 30 *Questionnaire of Cognitive Complaint [32]*

31 It is a yes/no 10 questions survey targeting memory, language, orientation, and behavior, enabling
32 clinicians to distinguish between a benign cognitive complaint and an at-risk complaint.
33

34 35 *Instrumental Activities of Daily Living (IADL) [33]*

36 Eight areas of daily functioning are measured with IADL scale, with a score ranging from 0 (dependent)
37 to 8 (independent) for women and from 0 to 5 for men.
38

39 40 *Pittsburg Sleep Quality Index (PSQI) [34]*

41 It is used to measure quality and sleep cycles in older adults by assessing seven sleep domains. It is
42 self-reported measure giving a global score ranging from 0 (no difficulties) to 21 (severe difficulties),
43 with the score higher than 5 reflecting disturbance of sleep and its quality.
44
45

46 47 *SF 12 [35]*

48 It is a self-reported 12 questions survey assessing the quality of life and more specifically the incidence
49 of health condition on daily living by exploring 8 areas. Two scores are calculated – a mental
50 component score (MCS-12) and a physical component score (PCS-12).
51
52

53 54 *Motivation scale for older adults [36]*

55 This scale measures intrinsic motivation, extrinsic self-determined and non-self-determined
56 motivation and amotivation in different life contexts. There are 12 motivational statements per life
57 context. Each of the statements is evaluated on a scale of 1 to 7 points.
58
59
60

5.3 Experimental Tasks

Four experimental tasks were constructed to measure near transfer of the effects of the training on executive functions and memory, the cognitive functions targeted by the training.

Stop Signal [37]

This task evaluates inhibition capacities. The participant is asked to give a response to the presentation of a target stimulus (Go signal) and to prevent this response when the stimulus is followed or preceded by a beep (Stop signal). The task includes two phases. The mean reaction time for each participant is calculated to be used in a second phase as a reference time for auditory signal presentation. In total, there are 96 trials. The trials are presented in randomized manner. The auditory signal presentation is adaptive. The first signal is presented after the stimulus presentation at reference time calculated in the phase 1. Each following signal is presented depending on the participant's capacity to withhold his/her response. If the participant succeeds, the time is increased by 10ms, if the participant fails the time is decreased by 10ms.

Letter and number pairs [38]

This task is used to evaluate mental flexibility. The participant sees 4 blocks of 48 letter-number pairs giving in total 192 trials presented in aleatory manner. Each pair appears for 350 ms on a computer screen, either in a square located in the upper part of the screen or in a square located in the lower part of the screen. The participant is asked to make a parity judgement if the pair appears at the upper part of the screen, and to make consonant/vowel judgement if it appears at the lower part of the screen. Reaction time and accuracy are recorded.

Up-dating span [38]

This task is used to evaluate up-dating in working memory. The series of letters appear on a computer screen, the participant is asked to memorize the last three presented letters, without knowing the length of the series. The series are presented in random order. Reaction time and accuracy are recorded.

Operation reading letters span [39]

This task is used to evaluate working memory. It consists of 8 series of 2 to 5 letters. The letters are separated by a presentation of one, two or three operands composed of one or two digits. The participant is asked to memorize each series of letters while reading aloud between each letter the operations and their results. In the end of the series the participant is asked to recall in serial order the letters.

6. Computer-based cognitive training

1
2
3 Training will be done for each participant over a period of 4 months on the PC computer with the
4 Happyneuron Pro software (<https://www.scientificbraintrainingpro.fr>). Patients will realize the
5 training as indicated in Design section, page 5. In the beginning of each session SLT will ask participant
6 to report any event that have occurred during the week and could in any way disturb his/her
7 participation to the training. These events will be reported in the EON. A 4-months training period is
8 justified by the fact that we wish to evaluate the benefits of a fairly short period that would be less
9 prone to drop out and whose duration is sufficient, according to the literature, to produce benefits.
10 We choose the training tool, Happyneuron Pro, because it is a well-known product for cognitive
11 remediation and frequently used by the SLTs in France, and in particular by SLTs participating to our
12 study.

13
14 Each training session of 45 minutes includes 10 exercises of different durations, but not exceeding 4
15 minutes (see Table 2 for details). The training program automatically stops after 45 minutes, even if
16 the patient has not completed the 10 exercises scheduled for the session. The training is adaptable
17 from session to session. Thus each session begins on the exercise and the level on which the previous
18 session stopped. Each exercise has 9 levels of difficulty and each level is displayed at least twice. This
19 is because the criterion for passing to a higher level of difficulty is to successfully execute the current
20 level two consecutive times.

21
22 The training targets the following cognitive functions: working and short-term memory, executive
23 functions, visuo-spatial capacities and processing speed.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Insert Table 2 here

7. Equipment and programming

The SLT's office and patient's personal computers are the only equipment used to run our protocol. All questionnaires and neuropsychological tests (except TMT and Figure from MMSE) were digitalized on Typeform. Experimental tasks were designed and programmed on the Open Sesame free access Software (Version 3.2.5). Thus, this software was installed on the SLT's computers. The training sessions were programmed on Happyneuron Pro Platform <https://www.scientificbraintrainingpro.fr/>

8. Study Management

8.1 General management

Each SLT participating in the study was provided an appropriate training to use all tools necessary for conducting the protocol. The training was delivered during videoconferences in small groups or individually and completed by e-mail exchanges and video tutorials, digital user guide, and power point presentations.

Each SLT has two personal spaces secured by password, one on the Happyneuron Pro platform to manage the trainings and another one on the Ennov Clinical containing the electronic observation notebooks (EON) of the patients to store all clinical information and results of neuropsychological tests and experimental tasks for each patient. It is hosted on the secured platform of Hospices Civils de Lyon (HCL). These personal areas are supervised by principal investigator, junior investigator of this study, and a clinical research assistant of HCL.

The workspace on Happyneuron Pro platform is used to create the training area for each included patient and to specify the frequency per week and the days of training sessions, depending on the training group. Once the patient's space is created and the sessions scheduled, the patient receives a link by email on the scheduled days and all he must do to access the training, is to click on the link.

The monitoring of the study is done by the Department of Clinical Research and Innovation of the Hospices Civils of Lyon². A designed clinical research assistant is in charge of the monitoring that includes :

- a study start-up visit to the coordinating center and the inclusion centers,
- a mid-term visit
- a closing visit

During mid-term and closing visits the verification of consent forms and EON will be done.

The coordinating center is composed of the three investigators (principal, senior and junior investigator) who designed the protocol and will be in charge of verification of inclusion/exclusion criteria before patients inclusion to the study and in the analysis of the data. These investigators are not involved in data collection.

8.2. Data management and storage

² HCL's identification code for the study 69HCL18_0881

1
2
3 The performance on the neuropsychological tests conducted via Typeform are automatically recorded.
4 When they are completed an email with the patients' scores is automatically sent to the investigator
5 and the SLT, and patients scores can be extracted from Typeform on Excel. In the end the SLT enters
6 the scores of interests into the patient's EON.
7
8

9 Performances on the experimental tasks are recorded on the SLT's office computer and then the scores
10 of interests are entered into the patient's EON.
11

12 The training results for each session are automatically recorded on a secure server hosted by a health
13 data host. There is no transit between servers, no storage of data on the patient computer. SLTs have
14 the possibility to monitor the trainings remotely: this is possible by accessing the patient's space,
15 enabling the SLTs to check if the training has been regularly carried out and to follow patients'
16 progression. If necessary, the SLT can also access the results online.
17

18 All the data entered in EON are accessible during the period of inclusion and after the end of the study
19 to the clinical research assistant in charge of the study monitoring and to the three investigators in
20 charge of this study and who do not take part in the data collection. The data extraction and analysis
21 are allowed at two points of the study, mid-term and the end of inclusion period. The final trail dataset
22 that will be used for statistical analysis will be accessible to the three investigators in charge of this
23 study.
24
25
26
27
28
29
30
31

32 33 34 35 **9. Statistical considerations**

36 37 **9.1 Estimation of samples size**

38 The sample size per training group was estimated on previous protocols and literature reviews [9, 40]
39 which show that the number of patients included in protocols varies between 15 and 150 per group.
40 Taking into account the data of previous studies and expected size effect, we decided to include 55
41 patients per group. Indeed, the size of each group was estimated to be 45, assuming a small effect of
42 the intervention (Cohen's $d = 0.40$), with a repeated measures factor Time of assessment (pre-training,
43 immediate post-training, long term post-training) and an independent measures factor of Group (MFG,
44 HFG, REG) to reach a power of 0.8 with an alpha at 0.05. We have estimated a 10% dropout rate by
45 the participants. Thus, we have estimated the inclusion of 50 patients per group. In addition, to
46 consider the cluster randomization we have estimated that we should increase our sample by 10%,
47 bringing the number of patients per group to 55. This number is compatible with our capacity of
48 patients' recruitment.
49
50
51
52
53
54
55
56
57

58 **9.2 Statistical methods description**

59
60

1
2
3 Linear models are considered for all behavioral measures collected with one random intercept per
4 patient and one per practice. The analysis will concern independent measures factor Group with three
5 modalities (MFG, HFG, REG) and repeated measures factor Time with three modalities (T0 - pre-
6 training, T1 - post-training, T2 - long term monitoring) and the interaction between these two factors.
7
8 Level of significance is fixed to 0.05.
9
10
11
12
13

14 The interim analyses are also planned, using the same models as described above, at three time points:
15 1 - after inclusion of 15 patients in each group, 2 - after inclusion of 30 patients in each group, and 3 -
16 after inclusion of 40 patients in each group. We decided to perform interim analyses to see if trends
17 would emerge on smaller samples than those estimated by the power analysis to be necessary to
18 obtain a training effect. These analyses are not intended to modify the protocol or the planned
19 inclusions.
20
21
22
23
24

25 Statistical analyses will be carried out using STATISTICA software.
26
27
28
29

30 **10. Risks and benefits**

31
32 There is no particular risk for patients to participate in this study. The only drawbacks could be
33 computer-related fatigue, especially for patients included in HFG.
34
35

36 The major personal benefit for patients would be an improvement in their cognitive and emotional
37 state or a slowing of the cognitive deficit progression. The secondary benefit could be the improvement
38 of their quality of life.
39
40

41 There is also a collective benefit since if the results of this study confirm our hypothesis, we could give
42 recommendations concerning at home training.
43
44
45
46

47 **11. Ethics and dissemination**

48 The study is conducted with ethics approval of the national ethical committee CPP Sud Méditerranée
49 III (Nr. 2019-A00458-49) and of the National Commission for Information Technology and Liberties (Nr.
50 919217). Any modification to the study design has to be communicated to the clinical research
51 assistant and if necessary a request for amendment must be addressed to the national ethical
52 committee who has delivered the approval for the study. The results of the study will be disseminated
53 in the form of oral communications or posters in international scientific conferences and seminars for
54 healthcare professionals (e.g., Alzheimer's Association International Conference, Union Nationale pour
55
56
57
58
59
60

1
2
3 le Développement de la Recherche et de l'Évaluation en Orthophonie) and published in a scientific journal
4 in the field (e.g., Journal of Alzheimer's Disease). The communications are allowed after the first
5 statistical analyses planned at the mid-time period of inclusion.
6
7
8
9

10 **12. Patient and Public Involvement**

11 Patients and public were not involved in any way in a conception of this study.
12
13

14 **13. Significance**

15
16 In a general way this study will contribute to the knowledge of cognitive training effects on cognition
17 in patients with Alzheimer's disease in the prodromal to moderate stages. The comparison of results
18 obtained for neuropsychological tests, questionnaires, and experimental tasks by REG patients with
19 those obtained by MFG patients will inform about the effects of at home cognitive training done as a
20 complement to training performed in SLT office. This will provide clear indications as about the
21 usefulness of this type of cognitive training program for AD patients. Comparison of results obtained
22 by MFG patients with those obtained by HFG patients will provide indications regarding the best
23 necessary frequency of the training sessions.
24
25
26
27
28
29
30
31

32
33 Beyond the benefits of cognitive training on the cognition of patients with AD, and the importance of
34 trying to determine the best frequency to obtain the optimal effects, other issues, that are
35 independent of the cognitive training program, may impact its success if they are not carefully
36 considered. The AD has an important impact on autonomy, emotional balance, and motivation, very
37 often linked to self-esteem [19-21]. Thus, it seems important, when designing cognitive training
38 protocols for AD patients, to consider psychological, environmental and autonomy factors for a more
39 optimal cognitive training plan, that seeks the well-being of the individual as a whole [21,41]. Through
40 questionnaires administered in our protocol [31-36], we hope to shed light on the emotional benefits
41 of training and answer questions regarding the commitment and adherence to the program by AD
42 patients, as well as to provide a more informed opinion on the importance of seeking assistance from
43 a third party. Understanding whether the same issues of autonomy in training are involved for patients
44 with mild and moderate AD will allow us to elaborate more precise computer-based home training
45 protocols for different patient's profile. These protocols should take into consideration the cognitive
46 decline severity that may affect autonomy in training as cognitive impairment increases. Such
47 considerations will bring us to foresee solutions when it comes to training performed at home for those
48 who are less autonomous.
49
50
51
52
53
54
55
56
57
58
59
60

References:

- [1] Cespón, J., Miniussi, C., Pellicciari, M.C. (2018). Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. *ScienceDirect Elsevier*, volume 43, 81-98. <https://doi.org/10.1016/j.arr.2018.03.001>
- [2] Günther, V. K., Schäfer, P., Holzner, B. J., & Kemmler, G. W. (2003). Long-term improvements in cognitive performance through computer-assisted cognitive training: a pilot study in a residential home for older people. *Aging & Mental Health*, 7(3), 200–206. <https://doi.org/10.1080/1360786031000101175>
- [3] Joubert, C., & Chainay, H. (2018). Aging brain: the effect of combined cognitive and physical training on cognition as compared to cognitive and physical training alone – a systematic review. *Clinical Interventions in Aging*, 13, 1267-1301. doi/10.2147/CIA.S165399
- [4] Chandler, M.J., Locke, D.E., Crook, J.E., et al., (2019). Comparative Effectiveness of Behavioral Interventions on Quality of Life for Older Adults With Mild Cognitive Impairment A Randomized Clinical Trial. *JAMA Network Open*. 2(5):e193016. doi:10.1001/jamanetworkopen.2019.3016
- [5] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation on the efficacy of strategic memory training in older adults: analysis of specific, transfer and maintenance effects. *Archives of Gerontology and Geriatrics*, 52(3), e192-197. <https://doi.org/10.1016/j.archger.2010.11.004>
- [6] Requena, C., Maestú, F., Campo, P., Fernández, A., Otiz, T. (2006). Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up. *Dementia and Geriatric Cognitive Disorders*, 22(4):339-345. DOI: 10.1159/000095600.
- [7] Joubert, C. & Chainay, H. (2019). Effects of cognitive and aerobic training on working memory and executive function in aging , a pseudo-randomised trial: Pilot study. *Journal of Ageing Research and Healthcare*, 2(3), 46-70. Doi:10.14302/issn.2474_7785.jarh-18-2458.
- [8] Kallio, E.L., Öhman, H., Kautiainen, H., Hietanen, Soini, H., Strandberg, T.E, Kautiainen, H., & Pitkälä, K. (2018). Effects of Cognitive Training on Cognition and Quality of Life of Older Persons with Dementia. *J Am Geriatr Soc*, 66: 664-670. <https://doi.org/10.1111/jgs.15196>
- [9] Gates, N. J., & Sachdev, P. S. (2014). Is cognitive training an effective treatment for preclinical and early Alzheimer's disease? *Journal of Alzheimer's Disease : JAD*, 42(Suppl), NaN-NaN. <https://doi.org/10.3233/JAD-141302>
- [10] Canu, E., Sarasso, E., Filippi, M., Agosta, F.(2018) Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's

1
2
3 disease and mild cognitive impairment: a critical review. *Alzheimer's Research & Therapy* volume 10,
4 Article number: 21.

5
6 [11] Galante, E., Venturini, G., & Fiaccadori, C. (2007). Computer-based cognitive intervention for
7 dementia: preliminary results of a randomized clinical trial. *Giornale Italiano Di Medicina Del Lavoro*
8 *Ed Ergonomia*, 29(3 Suppl B), B26-32.

9
10 [12] Lampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older
11 adults: a systematic review and meta-analysis of effect modifiers. (2014). *PLoS Med.*
12 2014;11(11):e1001756. doi:10.1371/journal.pmed.1001756

13
14 [13] Klimova B. (2016). Computer-Based Cognitive Training in Aging. *Frontiers in aging neuroscience*, 8,
15 313. <https://doi.org/10.3389/fnagi.2016.00313>

16
17 [14] Klimova, B., & Maresova, P. (2017). Computer-based training programs for older people with mild
18 cognitive impairment and/or dementia. *Frontiers in Human Neuroscience*, 11, Article 262.

19
20 [15] Choi, J., & Twamley, E. W. (2013). Cognitive rehabilitation therapies for Alzheimer's disease: a
21 review of methods to improve treatment engagement and self-efficacy. *Neuropsychology*
22 *Review*, 23(1), 48–62. <https://doi.org/10.1007/s11065-013-9227-4>

23
24 [16] Cavallo, M., & Angilletta, C. (2019). Long lasting neuropsychological effects of a computerized
25 cognitive training in patients affected by early stage Alzheimer's disease: Are they stable over time?
26 *Journal of Applied Gerontology*, 38(7), 1035-1044. Doi: 10.1177/0733464817750276

27
28 [17] García-Casal, J.A., Loizeau, A., Csipke, E., Franco-Martín, M., Perea-Bartolomé, M.V., & Orrell, M.
29 (2017). Computer-based cognitive interventions for people living with dementia: a systematic
30 literature review and meta-analysis. *Aging and Mental Health*, 21(5), 454-467.
31 doi:10.1080/13607863.2015.1132677

32
33 [18] Shao YK, Mang J, Li PL, Wang J, Deng T, Xu ZX. Computer-Based Cognitive Programs for
34 Improvement of Memory, Processing Speed and Executive Function during Age-Related Cognitive
35 Decline: A Meta-Analysis. (2015). *PLoS One.*;10(6):e0130831. Published 2015 Jun 22.
36 doi:10.1371/journal.pone.0130831

37
38 [19] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation
39 on the efficacy of strategic memory training in older adults: analysis of specific, transfer and
40 maintenance effects. *Archives of Gerontology and Geriatrics*, 52(3), e192-197.
41 <https://doi.org/10.1016/j.archger.2010.11.004>

42
43 [20] Jaeggi, S. M., Buschkuhl, M., Shah, P., & Jonides, J. (2014). The role of individual differences in
44 cognitive training and transfer. *Memory & Cognition*, 42(3), 464-480. [https://doi.org/10.3758/s13421-](https://doi.org/10.3758/s13421-013-0364-z)
45 013-0364-z

- 1
2
3 [21] Hwang, H. R., Choi, S. H., Yoon, D. H., Yoon, B.-N., Suh, Y. J., Lee, D., Hong, C.-G. (2012). The Effect
4 of Cognitive Training in Patients with Mild Cognitive Impairment and Early Alzheimer's Disease: A
5 Preliminary Study. *Journal of Clinical Neurology*, 8(3), 190. <https://doi.org/10.3988/jcn.2012.8.3.190>
6
7 [22] Belleville, S., & Boller, B. (2016). Comprendre le stade compensatoire de la maladie d'Alzheimer
8 et agir pour promouvoir la cognition et la plasticité cérébrale. [Understanding the compensatory stage
9 of Alzheimer's disease and acting to promote cognition and cerebral plasticity.]. *Canadian Journal of*
10 *Experimental Psychology/Revue Canadienne de Psychologie Expérimentale*, 70(4), 288–294.
11 <https://doi.org/10.1037/cep0000087>
12
13 [23] Förster, S., Buschert, V. C., Teipel, S. J., Friese, U., Buchholz, H.-G., Drzezga, A., ... Buerger, K. (2011).
14 Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnesic MCI and
15 Mild Alzheimer's Disease. *Journal of Alzheimer's Disease*, 26(s3), 337–348.
16 <https://doi.org/10.3233/JAD-2011-0025>
17
18 [24] Mendoza Laiz, N., Del Valle Diaz, S., Rioja Collado, N., Gomez-Pilar, J., & Hornero, R. (2018).
19 Potential Benefits of a Cognitive Training Program in Mild Cognitive Impairment (MCI). *Restorative*
20 *Neurology and Neuroscience*, 36(2): 207-213.
21 <http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/RNN-170754>
22
23 [25] Clare L, Evans S, Parkinson C, Woods R, Linden D. (2004). Cognitive training and cognitive
24 rehabilitation for people with early-stage Alzheimer's disease: A review: Neuropsychological
25 Rehabilitation: Vol 14, No 4. Retrieved September 27, 2018,
26 from <https://www.tandfonline.com/doi/abs/10.1080/09602010443000074>
27
28 [26] Realdon, O., Rossetto, F., Nalin, M., et al. (2016). Technology-Enhanced Multi-Domain at Home
29 Continuum of Care Program with Respect to Usual Care for People with Cognitive Impairment: The
30 Ability-Telrehabilitation study protocol for an randomized controlled trial. *BMC Psychiatry*, 16(1), 425.
31 <https://www.ncbi.nlm.nih.gov/pubmed/27887597>
32
33 [27] Croisile, B., Beaumont, C., Hadjedj, T., Riccio, J., & Astier, J.L. (2011). La Batterie
34 Neuropsychologique COurte (BANCO) : étalonnage chez 347 sujets normaux de 50 à 92 ans. *La Revue*
35 *De Gériatrie*, 36(9), 645–654.
36
37 [28] Reitan. R.M. (1958). Validity of the Trail Making Test as an Indicator of Organic Brain Damage, 8(3),
38 271–276. <https://doi.org/https://doi.org/10.2466/pms.1958.8.3.271>
39
40 [29] Erdodi, L.A., Abeare, C.A., Lichtenstein, J.D., Tyson, B.T., Kucharski, B., Zuccato, B.G., & Roth, R.M.
41 (2017). Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) processing speed scores as
42 measures of noncredible responding: The third generation of embedded performance validity
43 indicators. *Psychological Assessment*, 29(2), 148-157.
44 <https://doi.org/http://dx.doi.org/10.1037/pas0000319>
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [30] Kalafat, M., Hugonot-Diener, L., & Poitrenaud, J. (2003). French standardization of the mini mental
4 state (MMS), greco's version. *Revue de neuropsychologie*, 13(2), 209-236.
- 5
6 [31] Yesavage, J., Brink, T., Rose, T., Lum, o, Huang, V., Adey, M., & Leirer, V. (1982). Development and
7 validation of a geriatric
8 depression screening scale: a preliminary report. *Journal Of Psychiatric Research*, 17(1), 35-49.
- 9
10 [32] Thomas-Anterion, C., Ribas, C., Honore-Masson, S., Berne, G., Ruel, J.H., & Laurent, B. (2003). Le
11 Questionnaire de Plainte Cognitive (QPC) : Un outil de recherche de plainte suspecte d'évoquer une
12 Maladie d'Alzheimer ? *L'année Gerontologique*, 17, 56-65.
- 13
14 [33] Lawton, M. P., & Brody, E. M. (1970). Assessment Of Older People: Self Maintaining And
15 Instrumental Activities For Daily Living. *Nursing Research*, 19(3), 278.
- 16
17 [34] Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh
18 Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Research*, 28(2),
19 193-213.
- 20
21 [35] Ware, J. E., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction
22 of scales and preliminary tests of reliability and validity. *Medical Care*, 34(3), 220. Retrieved
23 from https://journals.lww.com/lwwmedicalcare/Abstract/1996/03000/A_12_Item_Short_Form_Health_Survey_Construction.3.aspx <http://dx.doi.org/10.1590/S1807-59322011000800015>
- 24
25 [36] Vallerand, R. J., & O'connor, B. P. (1991). Construction et Validation de l'Échelle de Motivation
26 pour les Personnes Âgées (Empa). *International Journal of Psychology*, 26(2), 219-240.
27 <https://doi.org/10.1080/00207599108247888>
- 28
29 [37] Amieva, H., Lafont, S., Auriacombe, S., Le Carret, N., Dartigues, J. F., Orgogozo, J. M., & Colette, F.
30 (2002). Inhibitory breakdown and dementia of the Alzheimer type: a general phenomenon?. *Journal*
31 *of clinical and experimental neuropsychology*, 24(4), 503-516.
32 <https://doi.org/10.1076/jcen.24.4.503.1034>
- 33
34 [38] Friedman, N. P., Miyake, A., & Young, Susan E. DeFries, John C. Corley, Robin P. Hewitt, John K.
35 (2008). Individual differences in executive functions are almost entirely genetic in origin. *Journal of*
36 *Experimental Psychology*, 137(2), 201-225. [https://doi.org/http://dx.doi.org/10.1037/0096-](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
37 [3445.137.2.201](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
- 38
39 [39] Barrouillet, P., Bernardin, S., & Camos, V. (2004). Time constraints and resource sharing in adults'
40 working memory spans. *Journal of Experimental Psychology. General*, 133(1), 83-100.
41 <https://doi.org/10.1037/0096-3445.133.1.83>
- 42
43 [40] Sherman, D.S., Mauster, J., Nuno, M., & Sherzai, D. (2017). The efficiency of Cognitive Intervention
44 in Mild Cognitive Impairment (MCI): a meta-analysis of outcomes on neuropsychological measures.
45 *Neuropsychological Review*, 27, 440-484. <https://doi.org/10.1007/s11065-017-9363-3>.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 [41] Kallio, E-L. (2019). *Effects of cognitive training on cognition and quality of life in older adults with*
4 *dementia*. Helsinki : [E.-L. Kallio].

5
6 [42] Cruz, V. T., Pais, J., Bento, V., Mateus, C., Colunas, M., Alves, I., ... Rocha, N. P. (2013). A
7 Rehabilitation Tool Designed for Intensive Web-Based Cognitive Training: Description and Usability
8 Study. *JMIR Research Protocols*, 2(2). <https://doi.org/10.2196/resprot.2899>
9

10 **Authors Contribution**

11
12 All the authors were involved in the study design and critically reviewed and approved the final
13 manuscript. SD drafted the manuscript.
14
15

16 **Fundings**

17
18 This research received no specific grant from any funding agency in the public, commercial or not-for-
19 profit sectors. The funding for this study is provided by SBT Human(s) Matter Company and Laboratoire
20 d'Etude des Mécanismes Cognitifs (Université Lyon 2) within a framework of the CIFRE (Convention
21 Industrielle de Formation par la Recherche – Industrial Agreement for Training through Research)
22 doctoral thesis.
23
24
25
26
27

28 **Competing interests' statement**

29
30 The authors declare that they have no known competing financial interest or personal relationship that
31 could have appeared to influence the work reported in this paper.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

321x118mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

190x271mm (72 x 72 DPI)

Boxes and Tables

| Box 1. Eligibility criteria | |
|---|--|
| Inclusion criteria: | |
| <ol style="list-style-type: none"> 1. Age \geq 60 years 2. Native French speaker 3. Diagnosis of Alzheimer's disease according to the DSM V criteria 4. Mild to moderate cognitive impairment as stage of disease progression (Mini-Mental State Examination $>15/30$) 5. Unchanged psychotropic treatment in the month prior to inclusion 6. Signed informed consent for a participation to the study (personally or by a legal representative) | |
| Exclusion criteria: | |
| <ol style="list-style-type: none"> 1. Uncorrected vision or hearing impairments 2. Motor dysfunction symptoms that could prevent the tests from being carried out 3. Not having a computer preventing cognitive training at home 4. Receiving SLT care for more than 3 months 5. Refusal to participate in the study 6. Being under guardianship or curatorship | |

Table 1. The main steps of the protocol process with the timetable.

| Steps | V0 Pre- inclusion | V1 Inclusion | V2 Assessment T0 | V3 à V19 Training | V20 Assessment T1 | V21 Assessment T2 |
|---|-------------------------|-----------------|------------------------|----------------------|-------------------------|-------------------------|
| Actions \ Time | D-30 à D-15 | J0 | S1 | S2-S17 | S18 | S30 |
| Allocation | X | | | | | |
| Eligibility screen | X | | | | | |
| Study presentation to the patient | X | | | | | |
| Signature of the informed consent | | X | | | | |
| Assessments (Neuropsychological tests, questionnaires and experimental tasks) | | | X | | X | X |
| Cognitive training | | | | | | |
| Group REG | | | | X | | |
| Group HFG | | | | X | | |
| Group MFG | | | | X | | |
| Collection of adverse events | | | X | X | X | X |

Table 2. Exercises included in cognitive training and cognitive capacity targeted by the exercise.

| Game type | Cognitive capacity targeted by the exercise |
|-------------------------------------|--|
| 1- Tower of Hanoi | - Problem solving |
| 2- Put some order in these accounts | - Visuospatial exploration - Attention and numerical processing |
| 3- Bird songs | - Auditory memory - Memorizing strategies |
| 4- Objects, where are you? | - Visuospatial memory - Binding capacities |
| 5- Find your way back. | - Visual short-term memory - Working memory |
| 6- Blazon Game | - Visual memory - Attention - Visuospatial perception |
| 7- Waiter please | - Verbal memory - Visual memory - Mental rotation ability |
| 8- Conduct the investigation | - Lexical comprehension - Categorization skills |
| 9- It is up to you to count | - Working memory - Mental arithmetic |
| 10- You have got a message | - Verbal-auditory memory |

COMITE DE PROTECTION DES PERSONNES SUD MEDITERRANEE III

Président: J-Y. LEFRANT Vice-Président: A-M. JOUBERT

Référence CPP à rappeler: 2019.04.08 ter_ 19.03.08.44936 Nîmes, le: 09 Décembre 2019

Lors de sa séance du: 05 décembre 2019 Présidée par Mme ou M: J-Y. LEFRANT

| En présence des membres suivants: Mmes et MM: | | Membres titulaires | | Membres suppléants | |
|---|--|--------------------|--|--------------------|---|
| 1 ^{er} Collège | Personnes qualifiées en recherche biomédicale | X | J-Y. LEFRANT S. DROUPY D. MOTTET | X | C. LECHICHE R. DE TAYRAC L. GONTHIER-MAURIN |
| | Compétents en biostatistique/épidémiologie | | C. DEMATTEI | X | S. BASTIDE |
| | Médecins généralistes | | P. SERAYET | X | C. GRAS-AYGON |
| | Pharmaciens hospitaliers | | A. MOURGUES | X | G. LEGUELINEL |
| 2 ^e Collège | Infirmiers | X | G. BAVILLE | | A. GIRON |
| | Compétents en questions éthiques | X | C. BERHAULT | X | V. ANTOINE |
| | Psychologues | X | L. HERITIER | | C. AYELA |
| | Travailleurs sociaux | | P. BERTAUDON | | |
| | Compétents en matière juridique | X | E. TOULOUSE-MULLER C. ROLLAND | | M. GRIT |
| Personnes cooptées | Représentants d'associations agréées de malades et usagers du système de santé | X | A-M. JOUBERT Y. PRIOUX | X | A. MENSUELLE-FERRARI |
| | Pédiatre | | | | |
| | Spécialiste pour défaut de consentement | | | | |

Les membres suivants s'étant retirés: Mmes et MM:

| | | |
|--|---|--|
| Le comité de protection des personnes Sud Méditerranée III a examiné les informations relatives à un projet référencé localement sous le numéro ci-dessus, et identifié par le numéro ci-dessous, relatif à: | | Recherche interventionnelle de type 1 |
| | X | Recherche interventionnelle de type 2 |
| | | Recherche non interventionnelle de type 3 |
| | | Utilisation d'éléments et produits du corps humain |
| | | Collection d'échantillons biologiques |

Numéro d'enregistrement: EudraCT ANSM 2019-A00458-49

Intitulé du projet: "MA-EIAD : Prise en charge de déficits cognitifs chez des patients atteints de la maladie d'Alzheimer au stade prodromal à modéré : Quels apports d'un entraînement informatisé à distance ?"

Promoteur HOSPICES CIVILS DE LYON

Investigateur principal ou coordonnateur: DR. CROISILE

Lieu de recherche (si soumis à autorisation):

| | | | | | |
|---|---|---------------------------------|-------------------|---|---|
| Au titre d'une demande d'avis concernant: | | Projet initial | Dans le cadre de: | X | Première soumission |
| | X | Modification substantielle N° 1 | | | Nouvelle soumission d'un projet modifié en réponse aux observations du comité |

Date de réception du projet visé 19 novembre 2019

| | | | |
|---|--|-------------------------------------|-------------|
| X | Le comité, ayant examiné ou réexaminé le projet soumis, exprime en séance plénière l'avis ci-contre: | X | Favorable |
| | Le projet ayant fait l'objet de réserves mineures lors de la délibération initiale, et celles-ci ayant été prises en compte, le comité exprime ce jour l'avis ci-contre: | | Défavorable |
| | | Différé | |
| | | P2P (sans 2 ^{ème} passage) | |
| | 2P (2 ^{ème} passage) | | |
| | Eclaircissements des réponses apportées | | |

Date de prise d'effet du présent avis: 05 décembre 2019

Le président: X Le vice-président: Le président de séance:

COMITE DE PROTECTION DES PERSONNES SUD MEDITERRANEE III

Président: J-Y. LEFRANT Vice-Président: A-M. JOUBERT

| | |
|---------------------------|---------------------------------|
| Référence CPP à rappeler: | 2019.04.08 ter _ 19.03.08.44936 |
|---------------------------|---------------------------------|

| Le présent avis concerne spécifiquement les documents suivants: | Version n° : | En date du: |
|---|--------------|------------------|
| <input checked="" type="checkbox"/> Courrier de demande | | 19 novembre 2019 |
| <input checked="" type="checkbox"/> Courrier de demande de modification substantielle | | 19 novembre 2019 |
| <input checked="" type="checkbox"/> Formulaire de demande | | 19 novembre 2019 |
| <input checked="" type="checkbox"/> Demande d'amendement au protocole | | 05 novembre 2019 |
| <input checked="" type="checkbox"/> Tableau comparatif des modifications | | |
| <input checked="" type="checkbox"/> Protocole | 4 | 18 novembre 2019 |
| <input checked="" type="checkbox"/> Résumé protocole | 5 | 18 novembre 2019 |
| <input checked="" type="checkbox"/> Note d'information et consentement destiné aux patients | 4 | 18 novembre 2019 |
| <input checked="" type="checkbox"/> Liste investigateur | 2 | 18 novembre 2019 |
| <input checked="" type="checkbox"/> CV du ou des investigateurs | | |

REMARQUES


(1) Le comité prend en considération pour sa décision les conditions de validité de la recherche au regard de la protection des personnes, notamment l'information des participants avant et pendant la durée de la recherche y compris l'adéquation, l'exhaustivité et l'intelligibilité des informations écrites, les modalités de recueil de leur consentement, les indemnités éventuellement dues, la pertinence générale du projet et l'adéquation entre les objectifs poursuivis et les moyens mis en œuvre, ainsi que la qualification du ou des investigateurs.

(2) Quel que soit l'avis du Comité, il ne dégage pas le promoteur de sa responsabilité.

(3) Conformément à la réglementation, tout avis est transmis à l'autorité compétente et, en cas d'avis défavorable, aux autres comités.

(4) En cas d'avis différé, le promoteur est invité à transmettre au comité dans les meilleurs délais les informations complémentaires demandées et/ou le projet modifié répondant aux réserves exprimées. Il peut demander, ainsi que l'investigateur principal, à être entendu par le comité.

MOTIVATION DE L'AVIS DU COMITE



Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Administrative information | | | |
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 1 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 7 |
| Protocol version | #3 | Date and version identifier | 5 |
| Funding | #4 | Sources and types of financial, material, and other support | 19 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 1;19 |

| | | | | |
|----|---------------------------|---------------------|--|-----|
| 1 | Roles and | #5b | Name and contact information for the trial sponsor | n/a |
| 2 | responsibilities: | | | |
| 3 | sponsor contact | | | |
| 4 | information | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | n/a |
| 8 | responsibilities: | | collection, management, analysis, and interpretation of data; | |
| 9 | sponsor and funder | | writing of the report; and the decision to submit the report for | |
| 10 | | | publication, including whether they will have ultimate authority | |
| 11 | | | over any of these activities | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating centre, | 11 |
| 17 | responsibilities: | | steering committee, endpoint adjudication committee, data | |
| 18 | committees | | management team, and other individuals or groups overseeing the | |
| 19 | | | trial, if applicable (see Item 21a for data monitoring committee) | |
| 20 | | | | |
| 21 | | | | |
| 22 | | | | |
| 23 | Introduction | | | |
| 24 | | | | |
| 25 | Background and | #6a | Description of research question and justification for undertaking | 4 |
| 26 | rationale | | the trial, including summary of relevant studies (published and | |
| 27 | | | unpublished) examining benefits and harms for each intervention | |
| 28 | | | | |
| 29 | | | | |
| 30 | Background and | #6b | Explanation for choice of comparators | n/a |
| 31 | rationale: choice of | | | |
| 32 | comparators | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | Objectives | #7 | Specific objectives or hypotheses | 4 |
| 36 | | | | |
| 37 | | | | |
| 38 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 5 |
| 39 | | | group, crossover, factorial, single group), allocation ratio, and | |
| 40 | | | framework (eg, superiority, equivalence, non-inferiority, | |
| 41 | | | exploratory) | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | Methods: | | | |
| 46 | Participants, | | | |
| 47 | interventions, and | | | |
| 48 | outcomes | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Study setting | #9 | Description of study settings (eg, community clinic, academic | 5 |
| 52 | | | hospital) and list of countries where data will be collected. | |
| 53 | | | Reference to where list of study sites can be obtained | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 6 |
| 58 | | | eligibility criteria for study centres and individuals who will | |
| 59 | | | | |
| 60 | | | | |

| | | | |
|----|------------------------------|--|-----|
| | | perform the interventions (eg, surgeons, psychotherapists) | |
| 1 | | | |
| 2 | Interventions: | #11a Interventions for each group with sufficient detail to allow | 10 |
| 3 | description | replication, including how and when they will be administered | |
| 4 | | | |
| 5 | Interventions: | #11b Criteria for discontinuing or modifying allocated interventions for a | n/a |
| 6 | modifications | given trial participant (eg, drug dose change in response to harms, | |
| 7 | | participant request, or improving / worsening disease) | |
| 8 | | | |
| 9 | Interventions: | #11c Strategies to improve adherence to intervention protocols, and any | n/a |
| 10 | adherence | procedures for monitoring adherence (eg, drug tablet return; | |
| 11 | | laboratory tests) | |
| 12 | Interventions: | #11d Relevant concomitant care and interventions that are permitted or | 6 |
| 13 | concomitant care | prohibited during the trial | |
| 14 | | | |
| 15 | Outcomes | #12 Primary, secondary, and other outcomes, including the specific | 7-9 |
| 16 | | measurement variable (eg, systolic blood pressure), analysis metric | |
| 17 | | (eg, change from baseline, final value, time to event), method of | |
| 18 | | aggregation (eg, median, proportion), and time point for each | |
| 19 | | outcome. Explanation of the clinical relevance of chosen efficacy | |
| 20 | | and harm outcomes is strongly recommended | |
| 21 | Participant timeline | #13 Time schedule of enrolment, interventions (including any run-ins | 7 |
| 22 | | and washouts), assessments, and visits for participants. A | |
| 23 | | schematic diagram is highly recommended (see Figure) | |
| 24 | | | |
| 25 | Sample size | #14 Estimated number of participants needed to achieve study | 12 |
| 26 | | objectives and how it was determined, including clinical and | |
| 27 | | statistical assumptions supporting any sample size calculations | |
| 28 | | | |
| 29 | Recruitment | #15 Strategies for achieving adequate participant enrolment to reach | 5 |
| 30 | | target sample size | |
| 31 | | | |
| 32 | | | |
| 33 | | | |
| 34 | | | |
| 35 | | | |
| 36 | | | |
| 37 | | | |
| 38 | | | |
| 39 | | | |
| 40 | | | |
| 41 | | | |
| 42 | | | |
| 43 | | | |
| 44 | | | |
| 45 | Methods: Assignment | | |
| 46 | of interventions (for | | |
| 47 | controlled trials) | | |
| 48 | | | |
| 49 | | | |
| 50 | Allocation: sequence | #16a Method of generating the allocation sequence (eg, computer- | n/a |
| 51 | generation | generated random numbers), and list of any factors for | |
| 52 | | stratification. To reduce predictability of a random sequence, | |
| 53 | | details of any planned restriction (eg, blocking) should be provided | |
| 54 | | in a separate document that is unavailable to those who enrol | |
| 55 | | participants or assign interventions | |
| 56 | | | |
| 57 | | | |
| 58 | | | |
| 59 | | | |
| 60 | | | |

| | | | | |
|----|------------------------|----------------------|--|---------|
| 1 | Allocation concealment | #16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | n/a |
| 2 | mechanism | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | 5-6 |
| 9 | implementation | | | |
| 10 | | | | |
| 11 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | n/a |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | n/a |
| 18 | emergency unblinding | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Methods: Data | | | |
| 23 | collection, | | | |
| 24 | management, and | | | |
| 25 | analysis | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | 7-9; 11 |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | Data collection plan: | #18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | n/a |
| 40 | retention | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | Data management | #19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | 12 |
| 45 | | | | |
| 46 | | | | |
| 47 | | | | |
| 48 | | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | 13 |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | n/a |
| 57 | analyses | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------------|----------------------|---|-----|
| 1 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non- | n/a |
| 2 | population and missing | | adherence (eg, as randomised analysis), and any statistical methods | |
| 3 | data | | to handle missing data (eg, multiple imputation) | |
| 4 | | | | |
| 5 | | | | |
| 6 | Methods: Monitoring | | | |
| 7 | | | | |
| 8 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary of its | 11 |
| 9 | formal committee | | role and reporting structure; statement of whether it is independent | |
| 10 | | | from the sponsor and competing interests; and reference to where | |
| 11 | | | further details about its charter can be found, if not in the protocol. | |
| 12 | | | Alternatively, an explanation of why a DMC is not needed | |
| 13 | | | | |
| 14 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 13 |
| 15 | interim analysis | | including who will have access to these interim results and make | |
| 16 | | | the final decision to terminate the trial | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Harms | #22 | Plans for collecting, assessing, reporting, and managing solicited | 10 |
| 23 | | | and spontaneously reported adverse events and other unintended | |
| 24 | | | effects of trial interventions or trial conduct | |
| 25 | | | | |
| 26 | | | | |
| 27 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, and | 11 |
| 28 | | | whether the process will be independent from investigators and the | |
| 29 | | | sponsor | |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | Ethics and | | | |
| 34 | dissemination | | | |
| 35 | | | | |
| 36 | Research ethics | #24 | Plans for seeking research ethics committee / institutional review | 13 |
| 37 | approval | | board (REC / IRB) approval | |
| 38 | | | | |
| 39 | | | | |
| 40 | Protocol amendments | #25 | Plans for communicating important protocol modifications (eg, | 13 |
| 41 | | | changes to eligibility criteria, outcomes, analyses) to relevant | |
| 42 | | | parties (eg, investigators, REC / IRBs, trial participants, trial | |
| 43 | | | registries, journals, regulators) | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |
| 47 | Consent or assent | #26a | Who will obtain informed consent or assent from potential trial | 6 |
| 48 | | | participants or authorised surrogates, and how (see Item 32) | |
| 49 | | | | |
| 50 | | | | |
| 51 | Consent or assent: | #26b | Additional consent provisions for collection and use of participant | n/a |
| 52 | ancillary studies | | data and biological specimens in ancillary studies, if applicable | |
| 53 | | | | |
| 54 | | | | |
| 55 | Confidentiality | #27 | How personal information about potential and enrolled participants | 6 |
| 56 | | | will be collected, shared, and maintained in order to protect | |
| 57 | | | confidentiality before, during, and after the trial | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|---|----------------------|---|-------|
| 1 | Declaration of interests | #28 | Financial and other competing interests for principal investigators for the overall trial and each study site | 19 |
| 2 | | | | |
| 3 | | | | |
| 4 | Data access | #29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | 12 |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Ancillary and post trial care | #30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | n/a |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | Dissemination policy: trial results | #31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | 13-14 |
| 15 | | | | |
| 16 | | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | Dissemination policy: authorship | #31b | Authorship eligibility guidelines and any intended use of professional writers | 19 |
| 22 | | | | |
| 23 | | | | |
| 24 | Dissemination policy: reproducible research | #31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | n/a |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Appendices | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Informed consent materials | #32 | Model consent form and other related documentation given to participants and authorised surrogates | n/a |
| 32 | | | | |
| 33 | | | | |
| 34 | Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | n/a |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |

40 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons
 41 Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a
 42 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59

BMJ Open

Study design and protocol of a low to high intensity computer-based cognitive training at home in supplement to standard care in patients with AD

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2021-050993.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 23-Dec-2021 |
| Complete List of Authors: | Dimachki, Samar; Université Lyon 2, Laboratoire d'Etude des Mécanismes Cognitifs Tarpin-Bernard, Franck; Université Grenoble Alpes UFR Informatique Mathématiques et Mathématiques Appliquées de Grenoble, Laboratoire d'informatique de Grenoble Croisile, Bernard; Hospices Civils de Lyon, Neurology Hospital - Neuropsychology Department Chainay, Hanna; Université Lumière Lyon 2, EMC Laboratory - (Etudes des Mécanismes Cognitifs) |
| Primary Subject Heading: | Complementary medicine |
| Secondary Subject Heading: | Geriatric medicine, Neurology, Mental health, Medical management, Palliative care |
| Keywords: | GERIATRIC MEDICINE, Dementia < NEUROLOGY, MENTAL HEALTH, PREVENTIVE MEDICINE, Delirium & cognitive disorders < PSYCHIATRY, COMPLEMENTARY MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11 **Study design and protocol of a low to high intensity computer-based**
12 **cognitive training at home in supplement to standard care in patients with AD**
13
14
15
16
17
18
19
20
21
22

23 Samar Dimachki^{1,3}, Franck Tarpin-Bernard^{2,3}, Bernard Croisile^{2,3} & Hanna Chainay¹
24
25
26
27

28 ¹Laboratoire d'Étude des Mécanismes Cognitifs, Université Lyon 2, Bron, France
29
30

31 ² Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital
32 Neurologique, Bron, France
33

34 ³Scientific Brain Training SA, Lyon, France
35
36

37 samar.dimachki@univ-lyon2.fr
38

39 f.tarpin@sbt-human.com
40

41 bernard.croisile@wanadoo.fr
42

43 hanna.chainay@univ-lyon2.fr
44

45 Corresponding author: Samar Dimachki
46

47 Université Lyon 2
48

49 Laboratoire d'Étude des Mécanismes Cognitifs
50

51 5 avenue Pierre Mendès France
52

53 69676 Bron, France
54

55 E-mail : samar.dimachki@univ-lyon2.fr
56

57 **Words count: 7583**
58

59 **Without references: 5830**
60

References: 1685

Abstract

Introduction: Recent studies on cognitive training in patients with Alzheimer's disease (AD) showed positive long-term effects on cognition and daily living, suggesting remote computer-based programs to increase training sessions while reducing patient's travelling. The aim of this study is to examine short- and long-term benefits of computer-based cognitive training at home in mild to moderate patients with AD, as a complement to the training in speech and language therapist (SLT) offices. The secondary purpose is to study training frequency required to obtain noticeable effects.

Methods and analysis: This is a national multi-center study, conducted in SLT offices. The patients follow training in one of three conditions: once a week in SLT office only (regular condition) and once a week in SLT office plus one or three times per week at home. The trainings' content in SLT office and at home are identical. For all three groups near and far transfer will be compared to evaluate training frequency's effect. Our primary outcome is executive and working memory scores in experimental tasks, and the secondary is neuropsychological tests and questionnaires' scores. Linear models' analysis are considered for all measures with a random intercept for patients and another for per practice. The fixed effects will be: three modality Groups and Time, repeated measures, (T0- pre-training, T1 - post-training, T2 - long-term follow-up) and the interaction pairs.

Ethics and dissemination: The study got ethics approval of the national ethical committee CPP Sud Méditerranée III (Nr. 2019-A00458-49) and of the National Commission for Information Technology and Liberties (Nr. 919217). Informed consent is obtained from each participant. Results will be disseminated in oral communications or posters in international conferences and published in scientific journals.

Trial registration number: ClinicalTrials.gov identifier (NCT04010175).

Keywords: Alzheimer's disease, MCI, computer-based cognitive training, at home cognitive training, cognitive benefits, quality of life

Strengths and limitations of the study

- ▶ This study will provide information on the short- and long-term effects of remote computer-based cognitive training in addition to regular training in SLT office for patients with AD.
- ▶ This study will shed light on the optimal cognitive training frequency to be administered.
- ▶ This study will evaluate the adherence to the computerized program at home in comparison with the trainings carried out exclusively in the SLT office, knowing that this factor is likely to be favorable to the adherence taking into account the reduction of travel and the training in a familiar environment.
- ▶ The limitation of the present study is that it will not control the familiarity of the Alzheimer's disease patients with the computer tool, nor their degree of autonomy in accomplishing the training at home on their own.

INTRODUCTION

Considering increasing occurrence of neurodegenerative disorders in the elderly, such as Alzheimer's disease (AD), and in the absence of effective drug treatment, usage of cognitive training seems to be a promising alternative in healthy and pathological aging for improving cognitive functioning [1-3] and quality of life [4-5]. For some researchers cognitive training also constitutes an added value to drug treatment, as it was observed to amplify the expression of drug effects [6].

The efficacy of cognitive training in patients with AD is still under the debate [7], especially concerning the best methodological approaches to be applied to optimize the training outcomes [8-9], including training feasibility, patient's commitment, and motivation. The computer-based cognitive training (CBCT) seems to have several advantages because it provides wide variety of well-calibrated exercises and allows for example to easily adapt their difficulty to each patient [10]. The CBCT short- and long-term benefits were first shown in healthy elderly [11,12], but have also been proven in patients with AD and MCI [13-17].

Several studies have highlighted the importance of some essential criteria for successful training, whatever its type [18, 14, 19]. Globally, the studies recommend early intervention with sessions between 30 minutes and 1 hour and session's frequency set at several times a week [8-9, 20]. Such a design is supposed to maintain strong commitment and motivation throughout the training, indispensable for its efficiency. However, these recommendations face some important problems that render their application difficult. First, few people are concerned about small changes in performance, the majority will only consult when symptoms become more pronounced, which prevents from early intervention suggested by several authors [20-24]. Second, patients' involvement in high frequency cognitive training protocols faces several difficulties, most importantly, frequent travels between home and speech-language pathologist's office (SPL). As the disease progresses, autonomy is compromised, and the need of a caregiver's help is a supplemental difficulty. In addition, the changing seasons lead to many health problems that hinder the training and often lead to interruptions. One way of circumventing these problems would be to propose a CBCT including some sessions at home [25,16]. Our main hypothesis is that remote cognitive training using computer-based programs is an effective way to increase the cognitive and psychological benefits of training as an outcome of training. We also hypothesized that more frequent training (e.g., several times per week) should bring more important benefits than training performed once a week.

The main objective of the present study is to examine the short- and long-term benefits of CBCT realized at home as a complement to in-office CBCT in mild to moderate patients with AD. The

1
2
3 secondary objective is to evaluate the best frequency of the at home training. To do so, we administer
4 computer-based cognitive training for 4 months under three conditions: (1) in SPL's office one-time
5 per week, (2) in SPL's office one time per week plus one time at home, and (3) in SPL's office one time
6 per week plus three times at home.
7
8
9

10 11 12 13 14 15 **Method**

16 17 18 **1. Design**

19
20 This is an experimental study with minimal risks, with 3 parallel groups, namely in SLT's office only
21 training group (REG – regular group), in SLT's office plus one session per week at home (MFG -
22 moderate frequency group) and in SLT's office plus three session per week at home (HFG – high
23 frequency group). The inclusion of patients will be done for 2 years, starting from the 1st September
24 2019 and ending 1st September 2021. For each participant, the inclusion period is approximately 8
25 months. During this period, participants cannot be included in other protocols that are susceptible to
26 influence their cognitive or emotional functions. The patients and their caregivers are informed about
27 this point before signing the informed consent and the SLTs are asked to monitor this throughout the
28 protocol. The total duration of the study is 32 months. All inclusions and testing will be realized in SLT
29 offices. The training will be done in SLT offices and at patients' homes (see Figure 1 for a study design).
30 The content of the trainings in SLT office and at home are identical.

31
32 This study obtained the authorization of the national ethical committee CPP Sud Méditerranée III (Nr.
33 2019-A00458-49, version 5 from 18/11/2019) and of the National Commission for Information
34 Technology and Liberties (Nr. 919217) and was registered on clinicaltrials.gov (NCT04010175).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **FIGURE 1**
52
53
54
55
56
57
58
59
60

2. Participants

This study concerns people over 60 years of age with a diagnosis of prodromal to moderate Alzheimer's disease. To recruit participants, we contacted SLTs subscribers to SBT's Happyneuron Pro digital tools through the SBT Human(s) Matter company network. They first answered a questionnaire in order to identify SLTs practicing with patients with AD. These SLT received an invitation letter for participation to our study. Finally, 27 SLTs from different parts of France joined the study and become clinical investigation centers (CIS). A full list of these SLTs can be obtained from the Department of Clinical Research and Innovation of the Hospices Civils of Lyon¹. Each SLT oversees presenting the study in his or her office to patients whose profile match our inclusion criteria. The interested patients will receive the information and consent leaflets. During the next visit they will be asked if he/she wished to participate to the study, and if so, the informed consent will be signed. Thus, the patients are included by the SLTs who also sign an informed consent after the neurologist's validation, the Principal Investigator of this study. Patients are informed that during the study they cannot take part in any other study that could potentially have an effect on their cognitive functions.

2.1 Eligibility

The eligibility criteria are presented in Box 1.

| Box 1. Eligibility criteria |
|---|
| <p>Inclusion criteria:</p> <ol style="list-style-type: none"> 1. Age \geq 60 years 2. Native French speaker 3. Diagnosis of Alzheimer's disease according to the DSM V criteria 4. Mild to moderate cognitive impairment as stage of disease progression (Mini-Mental State Examination $>15/30$) 5. Unchanged psychotropic treatment in the month prior to inclusion 6. Signed informed consent for a participation to the study (personally or by a legal representative) |
| <p>Exclusion criteria:</p> <ol style="list-style-type: none"> 1. Uncorrected vision or hearing impairments 2. Motor dysfunction symptoms that could prevent the tests from being carried out 3. Not having a computer preventing cognitive training at home 4. Receiving SLT care for more than 3 months 5. Refusal to participate in the study 6. Being under guardianship or curatorship |

¹ Direction de la Recherche Clinique, Hospice Civil de Lyon
3, quai des Célestins, 69229 Lyon Cedex 2

2.2 *Withdrawal Criteria*

Each patient is free to withdraw from the study at any time without giving the reasons, by simply informing one of the investigators. If consent is withdrawn, the data collected up to the date of withdrawal will be analyzed.

3. Randomization and Pseudonymization Method

To avoid any unequal treatment of patients in the same SLT, we decided to randomize SLTs' offices to different training groups, instead of randomizing patients. Thus, each office will be assigned to one of training group and all patients included in this SLT office will follow the same training procedure (REG, MFG or HFG). The offices will be assigned to each group in a balanced way in terms of socio-demographic considerations, depending on their geographical location. It will be done by a Head of Research & Development department in SBT before the study beginning. If, despite randomization, an imbalance occurs within groups due to inter-individual differences such as age, gender, education and disease severity, these factors would be considered as covariant in results analysis.

Each patient will receive a pseudonymized number composed, in order, of the number of the investigating center, the inclusion number for this center and the patient's initials. The SLT will keep the table of correspondence between this number and the first and last name, as well as the address and telephone number for all patients included in his/her center.

4. Procedure

Our study follows a conventional protocol used to evaluate the cognitive and psychological benefits resulting from cognitive training (for a review, [26]) (see Figure 2 and Table 1 for details). Each patient will be seen 21 times (Visit 1 to Visit 21). The content of each visit is described here below. Before the inclusion patients likely to take part in the study will be identified in speech and language therapy practices as part of their regular care. They will be informed by the speech therapist, co-investigator, about the study. The patient will be given any explanation necessary to fully understand the study, as well as an information letter explaining the objectives and the course of the protocol. The speech and language therapist will also give the patient a consent form in duplicate. The patient will be given one week to decide whether to take part in the study.

Inclusion visit - V1

If the patient agrees to take part in the study, the volunteer and the SLT (by delegation) will date and sign two copies of the consent form (one will be kept by the patient, the other will be kept by the SLT).

1
2
3 Assessment visit: pre-training - V2

4 During this visit, patients will undergo a series of experimental tasks, neuropsychological tests and
5 questionnaires that will serve as a baseline for our primary and secondary outcomes measures of the
6 effectiveness of the training.
7
8
9

10
11 Training visits - V3 to V19

12 Visits 3 to 19 will be devoted to training. These visits will be carried out at a frequency of once a week,
13 preferably on fixed days +/- 1 day. The patient will perform during about 45 minutes a series of short
14 training exercises involving memory, executive functions, processing speed, visuospatial abilities using
15 the Happyneuron Professional software (<https://www.happyneuronpro.com>). The number and nature
16 of the training sessions will be identical for all participants. However, the difficulty will be adapted
17 automatically by the software according to the patient's performance. The patients and their
18 caregivers are asked not to perform the cognitive exercises outside the training and the SLTs are asked
19 to monitor this throughout the protocol.
20
21

22 For all groups the SLT will appoint, if possible, a fixed day of a week for at office training. If the patient
23 misses this day, it will be rescheduled, if possible, to another day of the same week. For the HFG and
24 MFG groups which must train at home the SLT will fix the day(s) of trainings at home and patients and
25 their caregivers will receive the e-mail in the morning of the training day. If, despite of this, patient will
26 forget to train they will be allowed to train another day of the week. The SLT will be able to check
27 whether or not the patient trained on the scheduled day and if necessary, will contact patient or
28 his/her caregiver to reschedule the training for the next day. Patients are also informed that they can
29 ask the caregiver for a technical problem or to call his/her SLT.
30
31
32
33
34
35
36
37
38
39
40

41 Assessment visit: post-training - V20

42 During this visit patients will perform the same assessments as in the pre-training. This will allow intra-
43 group and inter-group comparisons of the effectiveness of the training in the three training conditions.
44
45
46
47

48 Assessment visit: long-term follow-up - V21

49 During this visit, patients will complete the same assessments as in the pre-training and post-training
50 visits. This will allow intra- and inter-group comparisons of the sustainability of training effectiveness.
51
52
53
54
55
56
57
58
59
60

Table 1. The main steps of the protocol process with the timetable.

| Steps | V0 Pre- inclusion | V1 Inclusion | V2 Assessment T0 | V3 to V19 Training | V20 Assessment T1 | V21 Assessment T2 |
|---|-------------------------|-----------------|------------------------|-----------------------|-------------------------|-------------------------|
| Time | D-30 à D-15 | D0 | W1 | W2-W17 | W18 | W30 |
| Allocation | X | | | | | |
| Eligibility screen | X | | | | | |
| Study presentation to the patient | X | | | | | |
| Signature of the informed consent | | X | | | | |
| Assessments (Neuropsychological tests, questionnaires and experimental tasks) | | | X | | X | X |
| Cognitive training | | | | | | |
| Group REG | | | | X | | |
| Group HFG | | | | X | | |
| Group MFG | | | | X | | |
| Collection of adverse events | | | X | X | X | X |

Note: V = Visit; W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency group; MHG = moderate frequency group.

5. Primary measures of training benefits

In order to test the effects of the training we will use three types of objective measures: experimental tasks, neuropsychological tests, and questionnaires. Our primary outcome measures are the scores obtained by patients with AD in executive and working memory experimental tasks. Our secondary outcome measures are the scores that patients will obtain on neuropsychological tests and questionnaires that will provide information on the overall level of improvement and above all, provide answers on the effect of the training on well-being and self-esteem. We will calculate the composite scores for our primary outcome measures. All measures will be performed in the three time-points (T0 – pre-training, T1 – immediately after training, and T2 – 3 months after training). The choice of these measures was made according to the trained cognitive functions and the cognitive (working memory, executive functions) and psychological (self-esteem, motivation, psychological state - depression/anxiety, assessment of quality of life) domains for which training benefits are expected. These evaluations enable us to first determine the baseline level of patient's cognitive capacities and his or her emotional and motivational state and second to measure the training benefice by comparing

1
2
3 the pre-training results (T0) with those obtained immediately after the end of the training (T1) and 3
4 months later (T2).
5
6
7

8 9 **5.1 Neuropsychological tests**

10 11 *Verbal Fluency [27]*

12 The overall objective of the fluency test is to evaluate executive functions by accessing patient's
13 capacity to access their lexical repertoire according to a given letter or a semantic category.
14
15

16 17 *TMT A/B [28]*

18 Trail Making Test consists of two parts. Part A measure processing speed – the patient must connect
19 in ascending order the 25 numbers randomly distributed in circles on the A4 page. Part B measure
20 cognitive flexibility – the patient must perform the same task as in part A while alternating between
21 numbers and letters (i.e., 1-A-2-B-3-C, etc.).
22
23
24

25 26 *Logical Memory [29]*

27 Logical Memory I and II are subtests of the *MEM Wechsler IV*. Each correctly recalled detail out of 25
28 details per story is scored 1 point, giving the maximum raw score of 50 points for two stories. Logical
29 Memory II is a delayed condition of Logical Memory I. The test ends with recognition, in which patient
30 must answer a series of questions concerning each story.
31
32
33

34 35 36 37 *MMSE [30]*

38 The Mini Mental State Examination (MMSE) is a commonly used test for screening general cognitive
39 impairment. The maximum MMSE score is 30 points.
40
41

42 43 *Digit Span [29]*

44 Two types of spans are used, forward and backward to measure respectively short-term and working
45 memory. For both span the test ends if the participant fails to repeat two consecutive series. The
46 maximum score is 48.
47
48
49

50 51 **5.2 Questionnaires**

52 53 54 *Geriatric Depression Scale (GDS) 30 items [31]*

55 GDS is 30 items, self-reported scale that uses "Yes/No" responses. It is used to detect the symptoms
56 of depression in older adults. Scores of 0-4 are considered normal, 5-8 indicate mild depression; 9-11
57 indicate moderate depression; and 12-15 indicate severe depression.
58
59
60

Questionnaire of Cognitive Complaint [32]

It is a yes/no 10 questions survey targeting memory, language, orientation, and behavior, enabling clinicians to distinguish between a benign cognitive complaint and an at-risk complaint.

Instrumental Activities of Daily Living (IADL) [33]

Eight areas of daily functioning are measured with IADL scale, with a score ranging from 0 (dependent) to 8 (independent) for women and from 0 to 5 for men.

Pittsburgh Sleep Quality Index (PSQI) [34]

It is used to measure quality and sleep cycles in older adults by assessing seven sleep domains. It is self-reported measure giving a global score ranging from 0 (no difficulties) to 21 (severe difficulties), with the score higher than 5 reflecting disturbance of sleep and its quality.

SF 12 [35]

It is a self-reported 12 questions survey assessing the quality of life and more specifically the incidence of health condition on daily living by exploring 8 areas. Two scores are calculated – a mental component score (MCS-12) and a physical component score (PCS-12).

Motivation scale for older adults [36]

This scale measures intrinsic motivation, extrinsic self-determined and non-self-determined motivation and amotivation in different life contexts. There are 12 motivational statements per life context. Each of the statements is evaluated on a scale of 1 to 7 points.

5.3 Experimental Tasks

Four experimental tasks were constructed to measure near transfer of the effects of the training on executive functions and memory, the cognitive functions targeted by the training.

Stop Signal [37]

This task evaluates inhibition capacities. The participant is asked to give a response to the presentation of a target stimulus (Go signal) and to prevent this response when the stimulus is followed or preceded by a beep (Stop signal). The task includes two phases. The mean reaction time for each participant is calculated to be used in a second phase as a reference time for auditory signal presentation. In total, there are 96 trials. The trials are presented in randomized manner. The auditory signal presentation is adaptive. The first signal is presented after the stimulus presentation at reference time calculated in the phase 1. Each following signal is presented depending on the participant's capacity to withhold his/her response. If the participant succeeds, the time is increased by 10ms, if the participant fails the time is decreased by 10ms.

Letter and number pairs [38]

This task is used to evaluate mental flexibility. The participant sees 4 blocks of 48 letter-number pairs giving in total 192 trials presented in aleatory manner. Each pair appears for 350 ms on a computer screen, either in a square located in the upper part of the screen or in a square located in the lower part of the screen. The participant is asked to make a parity judgement if the pair appears at the upper part of the screen, and to make consonant/vowel judgement if it appears at the lower part of the screen. Reaction time and accuracy are recorded.

Up-dating span [38]

This task is used to evaluate up-dating in working memory. The series of letters appear on a computer screen, the participant is asked to memorize the last three presented letters, without knowing the length of the series. The series are presented in random order. Reaction time and accuracy are recorded.

Operation reading letters span [39]

This task is used to evaluate working memory. It consists of 8 series of 2 to 5 letters. The letters are separated by a presentation of one, two or three operands composed of one or two digits. The participant is asked to memorize each series of letters while reading aloud between each letter the operations and their results. In the end of the series the participant is asked to recall in serial order the letters.

6. Computer-based cognitive training

Training will be done for each participant over a period of 4 months on the PC computer with the Happyneuron Pro software (<https://www.scientificbraintrainingpro.fr>). Patients will realize the training as indicated in Design section, page 5. In the beginning of each session SLT will ask participant to report any event that have occurred during the week and could in any way disturb his/her participation to the training. These events will be reported in the EON. A 4-months training period is justified by the fact that we wish to evaluate the benefits of a fairly short period that would be less prone to drop out and whose duration is sufficient, according to the literature, to produce benefits [40 - 41]. We choose the training tool, Happyneuron Pro², because it is a for well-known product cognitive remediation and frequently used by the SLTs in France, and in particular by SLTs participating to our study. Research and clinical studies have shown the effectiveness of the training

² Happyneuron Pro is a product developed by Scientific Brain Training.

programs proposed in the Happyneuron Pro software in improving cognitive functioning in patients suffering from different diseases and in normal aging [42 - 47]

Each training session of about 45 minutes includes 10 exercises of different durations, but not exceeding 4 minutes (see Table 2 for details). The training program automatically stops after 45 minutes, even if the patient has not completed the 10 exercises scheduled for the session. However, the session stops after the patient ended the in-hand exercise. The patients are not informed about the number of exercises they will perform during each session, they only know that each session will approximately last for 45 minutes. The training is adaptable from session to session. Thus, each session begins on the exercise and the level on which the previous session stopped. Each exercise has 9 levels of difficulty, and each level is displayed at least twice. This is because the criterion for passing to a higher level of difficulty is to successfully execute the current level two consecutive times.

The training targets the following cognitive functions: working and short-term memory, executive functions, visuo-spatial capacities, and processing speed (see Table 2 for more details).

Table 2. Exercises included in cognitive training and cognitive capacity targeted by the exercise.

| Game type | Cognitive capacity targeted by the exercise |
|-------------------------------------|--|
| 1- Tower of Hanoi | - Problem solving |
| 2- Put some order in these accounts | - Visuospatial exploration - Attention and numerical processing |
| 3- Bird songs | - Auditory memory - Memorizing strategies |
| 4- Objects, where are you? | - Visuospatial memory - Binding capacities |
| 5- Find your way back. | - Visual short-term memory - Working memory |
| 6- Blazon Game | - Visual memory - Attention - Visuospatial perception |
| 7- Waiter please | - Verbal memory - Visual memory - Mental rotation ability |
| 8- Conduct the investigation | - Lexical comprehension - Categorization skills |
| 9- It is up to you to count | - Working memory - Mental arithmetic |
| 10- You have got a message | - Verbal-auditory memory |

7. Equipment and programming

The SLT's office and patient's personal computers are the only equipment used to run our protocol. All questionnaires and neuropsychological tests (except TMT and Figure from MMSE) were digitalized on

Typeform. Experimental tasks were designed and programmed on the Open Sesame free access Software (Version 3.2.5). Thus, this software was installed on the SLT's computers. The training sessions were programmed on Happyneuron Pro Platform <https://www.scientificbraintrainingpro.fr/>

8. Study Management

8.1 General management

Each SLT participating in the study was provided an appropriate training to use all tools necessary for conducting the protocol. The training was delivered during videoconferences in small groups or individually and completed by e-mail exchanges and video tutorials, digital user guide, and power point presentations.

Each SLT has two personal spaces secured by password, one on the Happyneuron Pro platform to manage the trainings and another one on the Ennov Clinical containing the electronic observation notebooks (EON) of the patients to store all clinical information and results of neuropsychological tests and experimental tasks for each patient. It is hosted on the secured platform of Hospices Civils de Lyon (HCL). These personal areas are supervised by principal investigator, junior investigator of this study, and a clinical research assistant of HCL.

The workspace on Happyneuron Pro platform is used to create the training area for each included patient and to specify the frequency per week and the days of training sessions, depending on the training group. Once the patient's space is created and the sessions scheduled, the patient receives a link by email on the scheduled days and all he must do to access the training, is to click on the link.

The monitoring of the study is done by the Department of Clinical Research and Innovation of the Hospices Civils of Lyon³. A designed clinical research assistant is in charge of the monitoring that includes:

- a study start-up visit to the coordinating center and the inclusion centers,
- a mid-term visit
- a closing visit

During mid-term and closing visits the verification of consent forms and EON will be done.

³ HCL's identification code for the study 69HCL18_0881

1
2
3 The coordinating center is composed of the three investigators (principal, senior and junior
4 investigator) who designed the protocol and will be in charge of verification of inclusion/exclusion
5 criteria before patient's inclusion to the study and in the analysis of the data. These investigators are
6 not involved in data collection.
7
8
9

10 11 **8.2. Data management and storage**

12
13
14 The performance on the neuropsychological tests conducted via Typeform are automatically recorded.
15 When they are completed an email with the patients' scores is automatically sent to the investigator
16 and the SLT, and patients scores can be extracted from Typeform on Excel. In the end the SLT enters
17 the scores of interests into the patient's EON.
18

19
20 Performances on the experimental tasks are recorded on the SLT's office computer and then the scores
21 of interests are entered into the patient's EON.
22

23
24 The training results for each session are automatically recorded on a secure server hosted by a health
25 data host. There is no transit between servers, no storage of data on the patient computer. SLTs have
26 the possibility to monitor the trainings remotely: this is possible by accessing the patient's space,
27 enabling the SLTs to check if the training has been regularly carried out and to follow patients'
28 progression. If necessary, the SLT can also access the results online.
29

30
31 All the data entered in EON are accessible during the period of inclusion and after the end of the study
32 to the clinical research assistant in charge of the study monitoring and to the three investigators in
33 charge of this study and who do not take part in the data collection. The data extraction and analysis
34 are allowed at two points of the study, mid-term, and the end of inclusion period. The final trial dataset
35 that will be used for statistical analysis will be accessible to the three investigators in charge of this
36 study.
37
38
39
40
41
42
43
44

45 **9. Statistical considerations**

46 **9.1 Estimation of samples size**

47
48 The sample size per training group was estimated on previous protocols and literature reviews [8, 48]
49 which show that the number of patients included in protocols varies between 15 and 150 per group.
50 taking into account the data of previous studies and expected size effect, we decided to include 55
51 patients per group. Indeed, the size of each group was estimated to be 45, assuming a small effect of
52 the intervention (Cohen's $d = 0.40$), with a repeated measures factor Time of assessment (pre-training,
53 immediate post-training, long term post-training) and an independent measures factor of Group (MFG,
54 HFG, REG) to reach a power of 0.8 with an alpha at 0.05. We have estimated a 10% dropout rate by
55
56
57
58
59
60

1
2
3 the participants. Thus, we have estimated the inclusion of 50 patients per group. In addition, to
4 consider the cluster randomization we have estimated that we should increase our sample by 10%,
5 bringing the number of patients per group to 55. This number is compatible with our capacity of
6 patients' recruitment.
7
8
9

10 **9.2 Statistical methods description**

11
12 Linear models are considered for all behavioral measures collected with one random intercept per
13 patient and one per practice. The analysis will concern independent measures factor Group with three
14 modalities (MFG, HFG, REG) and repeated measures factor Time with three modalities (T0 - pre-
15 training, T1 - post-training, T2 - long term monitoring) and the interaction between these two factors.
16 Level of significance is fixed to 0.05. In our longitudinal analysis, we risk floor, ceiling, and curvilinear
17 effects since we have stopped the inclusion at an MMSE score higher than 15. For that reason, we plan
18 to adjust the initial values first, and to avoid the biases linked to the adjustment, we will refer to the
19 DAG (Causal Directed Acyclic) Graph. We will then apply methods that take into account the floor and
20 curvilinear effects, by adjusting the mean value of the observations, then through a linear mixed model
21 in a structural model we will study the evolution on the time axis and the common effects of the co-
22 variables.
23
24
25
26
27
28
29
30
31

32 The interim analyses are also planned, using the same models as described above, at three time points:
33 1 - after inclusion of 15 patients in each group, 2 - after inclusion of 30 patients in each group, and 3 -
34 after inclusion of 40 patients in each group. We decided to perform interim analyses to see if trends
35 would emerge on smaller samples than those estimated by the power analysis to be necessary to
36 obtain a training effect. These analyses are not intended to modify the protocol or the planned
37 inclusions.
38
39
40
41

42 Statistical analyses will be carried out using STATISTICA software.
43
44
45
46

47 **10. Risks and benefits**

48
49 There is no particular risk for patients to participate in this study. The only drawbacks could be
50 computer-related fatigue, especially for patients included in HFG.
51
52

53 The major personal benefit for patients would be an improvement in their cognitive and emotional
54 state or a slowing of the cognitive deficit progression. The secondary benefit could be the
55 improvement of their quality of life.
56
57
58
59
60

1
2
3 There is also a collective benefit since if the results of this study confirm our hypothesis, we could give
4 recommendations concerning at home training.
5
6
7

8 **11. Ethics and dissemination**

9
10 The study is conducted with ethics approval of the national ethical committee (CPP – Comité de
11 Protection des Personnes, Sud Méditerranée III, Nr. 2019) and of the National Commission for
12 Information Technology and Liberties (Nr. 919217). Any modification to the study design has to be
13 communicated to the clinical research assistant and if necessary, a request for amendment must be
14 addressed to the national ethical committee who has delivered the approval for the study. The results
15 of the study will be disseminated in the form of oral communications or posters in international
16 scientific conferences and seminars for healthcare professionals (e.g., Alzheimer's Association
17 International Conference, Union Nationale pour le Développement de la Recherche et de l'Évaluation en
18 Orthophonie) and published in a scientific journal in the field (e.g., Journal of Alzheimer's Disease). The
19 communications are allowed after the first statistical analyses planned at the mid-time period of
20 inclusion.
21
22
23
24
25
26
27
28

29 **12. Significance**

30
31
32 In a general way this study will contribute to the knowledge of cognitive training effects on cognition
33 in patients with AD in the prodromal to moderate stages. The comparison of results obtained for
34 neuropsychological tests, questionnaires, and experimental tasks by REG patients with those obtained
35 by MFG patients will inform about the effects of at home cognitive training done as a complement to
36 training performed in SLT office. This will provide clear indications as about the usefulness of this type
37 of cognitive training program for patients with AD. Comparison of results obtained by MFG patients
38 with those obtained by HFG patients will provide indications regarding the best necessary frequency
39 of the training sessions.
40
41
42
43
44
45

46 Beyond the benefits of cognitive training on the cognition of patients with AD, and the importance of
47 trying to determine the best frequency to obtain the optimal effects, other issues, that are
48 independent of the cognitive training program, may impact its success if they are not carefully
49 considered. AD has an important impact on autonomy, emotional balance, and motivation, very often
50 linked to self-esteem [18-20]. Thus, it seems important, when designing cognitive training protocols
51 for patients with AD to consider psychological, environmental and autonomy factors for a more
52 optimal cognitive training plan, that seeks the well-being of the individual as a whole [20,48-49].
53 Through questionnaires administered in our protocol [31-36], we hope to shed light on the emotional
54 benefits of training and answer questions regarding the commitment and adherence to the program
55
56
57
58
59
60

1
2
3 patients with AD as well as to provide a more informed opinion on the importance of seeking assistance
4 from a third party. Understanding whether the same issues of autonomy in training are involved for
5 patients with mild and moderate AD will allow us to elaborate more precise computer-based home
6 training protocols for different patient's profile. These protocols should take into consideration the
7 cognitive decline severity that may affect autonomy in training as cognitive impairment increases. Such
8 considerations will bring us to foresee solutions when it comes to training performed at home for those
9 who are less autonomous.
10
11
12
13
14
15
16
17
18
19

20 **Authors Contribution**

21
22 Author Contributions: Conceptualization, S.D. and H.C.; Data treatment, S.D.; Project administration,
23 S.D. and H.C., Supervision, H.C., F.T-B., B.C.; Writing—Original draft, S.D. and H.C.; Writing—Review &
24 editing, S.D., H.C., F.T-B. and B.C. All authors have read and agreed to the submitted version of the
25 manuscript.
26
27
28
29

30 **Fundings**

31
32 The funding for this study is provided by SBT Humans Matter Company and Laboratoire d'Etude des
33 Mécanismes Cognitifs (Université Lyon 2) within a framework of the CIFRE (Convention Industrielle de
34 Formation par la Recherche – Industrial Agreement for Training through Research) doctoral thesis
35 financed by ANRT French agency.
36
37
38
39

40 **Competing interests' statement**

41
42 Franck Tarpin-Bernard and Bernard Croisile are cofounders and shareholders of SBT Humans Matter.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

- [1] Cespón, J., Miniussi, C., Pellicciari, M.C. (2018). Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. *ScienceDirect Elsevier*, volume 43, 81-98. <https://doi.org/10.1016/j.arr.2018.03.001>
- [2] Günther, V. K., Schäfer, P., Holzner, B. J., & Kemmler, G. W. (2003). Long-term improvements in cognitive performance through computer-assisted cognitive training: a pilot study in a residential home for older people. *Aging & Mental Health*, 7(3), 200–206. <https://doi.org/10.1080/1360786031000101175>
- [3] Joubert, C., & Chainay, H. (2018). Aging brain: the effect of combined cognitive and physical training on cognition as compared to cognitive and physical training alone – a systematic review. *Clinical Interventions in Aging*, 13, 1267-1301. doi/10.2147/CIA.S165399
- [4] Chandler, M.J., Locke, D.E., Crook, J.E., et al., (2019). Comparative Effectiveness of Behavioral Interventions on Quality of Life for Older Adults With Mild Cognitive Impairment A Randomized Clinical Trial. *JAMA Network Open*. 2(5):e193016. doi:10.1001/jamanetworkopen.2019.3016
- [5] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation on the efficacy of strategic memory training in older adults: analysis of specific, transfer and maintenance effects. *Archives of Gerontology and Geriatrics*, 52(3), e192-197. <https://doi.org/10.1016/j.archger.2010.11.004>
- [6] Requena, C., Maestú, F., Campo, P., Fernández, A., Otiz, T. (2006). Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up. *Dementia and Geriatric Cognitive Disorders*, 22(4):339-345. DOI: 10.1159/000095600.
- [7] Kallio, E.L., Öhman, H., Kautiainen, H., Hietanen, Soini, H., Strandberg, T.E, Kautiainen, H., & Pitkälä, K. (2018). Effects of Cognitive Training on Cognition and Quality of Life of Older Persons with Dementia. *J Am Geriatr Soc*, 66: 664-670. <https://doi.org/10.1111/jgs.15196>
- [8] Gates, N. J., & Sachdev, P. S. (2014). Is cognitive training an effective treatment for preclinical and early Alzheimer's disease? *Journal of Alzheimer's Disease: JAD*, 42(Suppl), NaN-NaN. <https://doi.org/10.3233/JAD-141302>
- [9] Canu, E., Sarasso, E., Filippi, M., Agosta, F.(2018) Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review. *Alzheimer's Research & Therapy* volume 10, Article number: 21.
- [10] Galante, E., Venturini, G., & Fiaccadori, C. (2007). Computer-based cognitive intervention for dementia: preliminary results of a randomized clinical trial. *Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia*, 29(3 Suppl B), B26-32.

- 1
2
3 [11] Lampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older
4 adults: a systematic review and meta-analysis of effect modifiers. (2014). *PLoS Med.*
5 2014;11(11):e1001756. doi:10.1371/journal.pmed.1001756
6
7
8 [12] Klimova B. (2016). Computer-Based Cognitive Training in Aging. *Frontiers in aging neuroscience, 8*,
9 313. <https://doi.org/10.3389/fnagi.2016.00313>
10
11 [13] Klimova, B., & Maresova, P. (2017). Computer-based training programs for older people with mild
12 cognitive impairment and/or dementia. *Frontiers in Human Neuroscience, 11*, Article 262.
13
14 [14] Choi, J., & Twamley, E. W. (2013). Cognitive rehabilitation therapies for Alzheimer's disease: a
15 review of methods to improve treatment engagement and self-efficacy. *Neuropsychology*
16 *Review, 23*(1), 48–62. <https://doi.org/10.1007/s11065-013-9227-4>
17
18 [15] Cavallo, M., & Angilletta, C. (2019). Long lasting neuropsychological effects of a computerized
19 cognitive training in patients affected by early stage Alzheimer's disease: Are they stable over time?
20 *Journal of Applied Gerontology, 38*(7), 1035-1044. Doi: 10.1177/0733464817750276
21
22 [16] García-Casal, J.A., Loizeau, A., Csipke, E., Franco-Martín, M., Perea-Bartolomé, M.V., & Orrell, M.
23 (2017). Computer-based cognitive interventions for people living with dementia: a systematic
24 literature review and meta-analysis. *Aging and Mental Health, 21*(5), 454-467.
25 doi:10.1080/13607863.2015.1132677
26
27 [17] Shao YK, Mang J, Li PL, Wang J, Deng T, Xu ZX. Computer-Based Cognitive Programs for
28 Improvement of Memory, Processing Speed and Executive Function during Age-Related Cognitive
29 Decline: A Meta-Analysis. (2015). *PLoS One.*;10(6):e0130831. Published 2015 Jun 22.
30 doi:10.1371/journal.pone.0130831
31
32 [18] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation
33 on the efficacy of strategic memory training in older adults: analysis of specific, transfer and
34 maintenance effects. *Archives of Gerontology and Geriatrics, 52*(3), e192-197.
35 <https://doi.org/10.1016/j.archger.2010.11.004>
36
37 [19] Jaeggi, S. M., Buschkuhl, M., Shah, P., & Jonides, J. (2014). The role of individual differences in
38 cognitive training and transfer. *Memory & Cognition, 42*(3), 464-480. [https://doi.org/10.3758/s13421-](https://doi.org/10.3758/s13421-013-0364-z)
39 013-0364-z
40
41 [20] Hwang, H. R., Choi, S. H., Yoon, D. H., Yoon, B.-N., Suh, Y. J., Lee, D., Hong, C.-G. (2012). The Effect
42 of Cognitive Training in Patients with Mild Cognitive Impairment and Early Alzheimer's Disease: A
43 Preliminary Study. *Journal of Clinical Neurology, 8*(3), 190. <https://doi.org/10.3988/jcn.2012.8.3.190>
44
45 [21] Belleville, S., & Boller, B. (2016). Comprendre le stade compensatoire de la maladie d'Alzheimer
46 et agir pour promouvoir la cognition et la plasticité cérébrale. [Understanding the compensatory stage
47 of Alzheimer's disease and acting to promote cognition and cerebral plasticity.]. *Canadian Journal of*
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Experimental Psychology/Revue Canadienne de Psychologie Expérimentale*, 70(4), 288–294.
4 <https://doi.org/10.1037/cep0000087>

5
6 [22] Förster, S., Buschert, V. C., Teipel, S. J., Friese, U., Buchholz, H.-G., Drzezga, A., ... Buerger, K. (2011).
7 Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnesic MCI and
8 Mild Alzheimer's Disease. *Journal of Alzheimer's Disease*, 26(s3), 337–348.
9 <https://doi.org/10.3233/JAD-2011-0025>

10 [23] Mendoza Laiz, N., Del Valle Diaz, S., Rioja Collado, N., Gomez-Pilar, J., & Hornero, R. (2018).
11 Potential Benefits of a Cognitive Training Program in Mild Cognitive Impairment (MCI). *Restorative*
12 *Neurology and Neuroscience*, 36(2): 207-213.
13 <http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/RNN-170754>

14 [24] Clare L, Evans S, Parkinson C, Woods R, Linden D. (2004). Cognitive training and cognitive
15 rehabilitation for people with early-stage Alzheimer's disease: A review: Neuropsychological
16 Rehabilitation: Vol 14, No 4. Retrieved September 27, 2018,
17 from <https://www.tandfonline.com/doi/abs/10.1080/09602010443000074>

18 [25] Realdon, O., Rossetto, F., Nalin, M., et al. (2016). Technology-Enhanced Multi-Domain at Home
19 Continuum of Care Program with Respect to Usual Care for People with Cognitive Impairment: The
20 Ability-Telrehabilitation study protocol for an randomized controlled trial. *BMC Psychiatry*, 16(1), 425.
21 <https://www.ncbi.nlm.nih.gov/pubmed/27887597>

22 [26] Cruz, V. T., Pais, J., Bento, V., Mateus, C., Colunas, M., Alves, I., ... Rocha, N. P. (2013). A
23 Rehabilitation Tool Designed for Intensive Web-Based Cognitive Training: Description and Usability
24 Study. *JMIR Research Protocols*, 2(2). <https://doi.org/10.2196/resprot.2899>

25 [27] Croisile, B., Beaumont, C., Hadjedj, T., Riccio, J., & Astier, J.L. (2011). La Batterie
26 Neuropsychologique Courte (BANCO) : étalonnage chez 347 sujets normaux de 50 à 92 ans. *La Revue*
27 *De Gériatrie*, 36(9), 645–654.

28 [28] Reitan. R.M. (1958). Validity of the Trail Making Test as an Indicator of Organic Brain Damage, 8(3),
29 271–276. <https://doi.org/https://doi.org/10.2466/pms.1958.8.3.271>

30 [29] Erdodi, L.A., Abeare, C.A., Lichtenstein, J.D., Tyson, B.T., Kucharski, B., Zuccato, B.G., & Roth, R.M.
31 (2017). Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) processing speed scores as
32 measures of noncredible responding: The third generation of embedded performance validity
33 indicators. *Psychological Assessment*, 29(2), 148-157.
34 <https://doi.org/http://dx.doi.org/10.1037/pas0000319>

35 [30] Kalafat, M., Hugonot-Diener, L., & Poitrenaud, J. (2003). French standardization of the mini mental
36 state (MMS), greco's version. *Revue de neuropsychologie*, 13(2), 209-236.

- 1
2
3 [31] Yesavage, J., Brink, T., Rose, T., Lum, o, Huang, V., Adey, M., & Leirer, V. (1982). Development and
4 validation of a geriatric
5 depression screening scale: a preliminary report. *Journal Of Psychiatric Research*, 17(1), 35–49.
6
7 [32] Thomas-Anterion, C., Ribas, C., Honore-Masson, S., Berne, G., Ruel, J.H., & Laurent, B. (2003). Le
8 Questionnaire de Plainte Cognitive (QPC) : Un outil de recherche de plainte suspecte d'évoquer une
9 Maladie d'Alzheimer ? *L'année Gerontologique*, 17, 56–65.
10
11 [33] Lawton, M. P., & Brody, E. M. (1970). Assessment Of Older People: Self Maintaining And
12 Instrumental Activities For Daily Living. *Nursing Research*, 19(3), 278.
13
14 [34] Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh
15 Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry*
16 *Research*, 28(2), 193–213.
17
18 [35] Ware, J. E., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction
19 of scales and preliminary tests of reliability and validity. *Medical Care*, 34(3), 220. Retrieved
20 from https://journals.lww.com/lwwmedicalcare/Abstract/1996/03000/A_12_Item_Short_Form_Health_Survey_Construction.3.aspx <http://dx.doi.org/10.1590/S1807-59322011000800015>
21
22 [36] Vallerand, R. J., & O'connor, B. P. (1991). Construction et Validation de l'Échelle de Motivation
23 pour les Personnes Âgées (Empa). *International Journal of Psychology*, 26(2), 219–240.
24 <https://doi.org/10.1080/00207599108247888>
25
26 [37] Amieva, H., Lafont, S., Auriacombe, S., Le Carret, N., Dartigues, J. F., Orgogozo, J. M., & Colette, F.
27 (2002). Inhibitory breakdown and dementia of the Alzheimer type: a general phenomenon?. *Journal*
28 *of clinical and experimental neuropsychology*, 24(4), 503–516.
29 <https://doi.org/10.1076/jcen.24.4.503.1034>
30
31 [38] Friedman, N. P., Miyake, A., & Young, Susan E. DeFries, John C. Corley, Robin P. Hewitt, John K.
32 (2008). Individual differences in executive functions are almost entirely genetic in origin. *Journal of*
33 *Experimental Psychology*, 137(2), 201–225. [https://doi.org/http://dx.doi.org/10.1037/0096-](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
34 [3445.137.2.201](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
35
36 [39] Barrouillet, P., Bernardin, S., & Camos, V. (2004). Time constraints and resource sharing in adults'
37 working memory spans. *Journal of Experimental Psychology. General*, 133(1), 83–100.
38 <https://doi.org/10.1037/0096-3445.133.1.83>
39
40 [40] Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., & Lyketsos, C. (2010).
41 Management of behavioral problems in Alzheimer's disease. *International Psychogeriatrics*, 22(3),
42 346–372. <https://doi.org/10.1017/S1041610209991505>
43
44 [41] Choi, J., & Twamley, E. W. (2013). Cognitive Rehabilitation Therapies for Alzheimer's Disease: A
45 Review of Methods to Improve Treatment Engagement and Self-Efficacy. *Neuropsychology Review*,
46 23(1), 48–62. <https://doi.org/10.1007/s11065-013-9227-4>
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [42] Vianin, P., Urben, S., Magistretti, P., Marquet, P., Fornari, E., & Jaugey, L. (2014). Increased
4 activation in Broca's area after cognitive remediation in schizophrenia. *Psychiatry Research:*
5 *Neuroimaging*, 221(3), 204–209. <https://doi.org/10.1016/j.psychresns.2014.01.004>
6
7
8 [43] Demily, C., Rigard, C., Peyroux, E., Chesnoy-Servanin, G., Morel, A., & Franck, N. (2016). «Cognitus
9 & Moi»: A Computer-Based Cognitive Remediation Program for Children with Intellectual Disability.
10 *Frontiers in Psychiatry*, 7. <https://doi.org/10.3389/fpsyt.2016.00010>
11
12
13 [44] Bowie, C. R., Gupta, M., Holshausen, K., Jokic, R., Best, M., & Milev, R. (2013). Cognitive
14 Remediation for Treatment-Resistant Depression: Effects on Cognition and Functioning and the Role
15 of Online Homework. *Journal of Nervous & Mental Disease*, 201(8), 680–685.
16 <https://doi.org/10.1097/NMD.0b013e31829c5030>
17
18
19 [45] Bobillier Chaumon, M.-E., Michel, C., Tarpin Bernard, F., & Croisile, B. (2014). Can ICT improve the
20 quality of life of elderly adults living in residential home care units? From actual impacts to hidden
21 artefacts. *Behaviour & Information Technology*, 33(6), 574–590.
22 <https://doi.org/10.1080/0144929X.2013.832382>
23
24
25 [46] Joubert, C., & Chainay, H. (2019). Effects of Cognitive and Aerobic training on Working Memory
26 and Executive Function in Aging, a Pseudo-Randomized Trial: Pilot Study. *Journal of Aging Research*
27 *and Healthcare*, 2(3), 46–70. <https://doi.org/10.14302/issn.2474-7785.jarh-18-2458>
28
29
30 [47] Franck, N. (2013). Clinique de la schizophrénie. *EMC - Psychiatrie*, 10(1), 1–16.
31 [https://doi.org/10.1016/S0246-1072\(12\)59577-5](https://doi.org/10.1016/S0246-1072(12)59577-5)
32
33
34 [48] Sherman, D.S., Mauster, J., Nuno, M., & Sherzai, D. (2017). The efficiency of Cognitive Intervention
35 in Mild Cognitive Impairment (MCI): a meta-analysis of outcomes on neuropsychological measures.
36 *Neuropsychological Review*, 27, 440-484. <https://doi.org/10.1007/s11065-017-9363-3>.
37
38
39 [49] Kallio, E.-L. (2019). *Effects of cognitive training on cognition and quality of life in older adults with*
40 *dementia*. Helsinki : [E.-L. Kallio].
41
42
43
44

45 Figure legend

46
47 Figure 1: illustrating on the time axis the evolution of the experiment with the facts marked on a weekly basis
48 trainings take place between the 2nd and the 17th week for the 3 training groups simultaneously. Note: V = Visit;
49 W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency group; MHG =
50 moderate frequency group.
51
52
53
54
55
56
57
58
59
60




Figure 1: illustrating on the time axis the evolution of the experiment with the facts marked on a weekly basis trainings take place between the 2nd and the 17th week for the 3 training groups simultaneously. Note: V = Visit; W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency group; MHG = moderate frequency group.

321x118mm (72 x 72 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Administrative information | | | |
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 1 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 7 |
| Protocol version | #3 | Date and version identifier | 5 |
| Funding | #4 | Sources and types of financial, material, and other support | 19 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 1;19 |

| | | | | |
|----|---------------------------|---------------------|--|-----|
| 1 | Roles and | #5b | Name and contact information for the trial sponsor | n/a |
| 2 | responsibilities: | | | |
| 3 | sponsor contact | | | |
| 4 | information | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | n/a |
| 8 | responsibilities: | | collection, management, analysis, and interpretation of data; | |
| 9 | sponsor and funder | | writing of the report; and the decision to submit the report for | |
| 10 | | | publication, including whether they will have ultimate authority | |
| 11 | | | over any of these activities | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating centre, | 11 |
| 17 | responsibilities: | | steering committee, endpoint adjudication committee, data | |
| 18 | committees | | management team, and other individuals or groups overseeing the | |
| 19 | | | trial, if applicable (see Item 21a for data monitoring committee) | |
| 20 | | | | |
| 21 | | | | |
| 22 | | | | |
| 23 | Introduction | | | |
| 24 | | | | |
| 25 | Background and | #6a | Description of research question and justification for undertaking | 4 |
| 26 | rationale | | the trial, including summary of relevant studies (published and | |
| 27 | | | unpublished) examining benefits and harms for each intervention | |
| 28 | | | | |
| 29 | | | | |
| 30 | Background and | #6b | Explanation for choice of comparators | n/a |
| 31 | rationale: choice of | | | |
| 32 | comparators | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | Objectives | #7 | Specific objectives or hypotheses | 4 |
| 36 | | | | |
| 37 | | | | |
| 38 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 5 |
| 39 | | | group, crossover, factorial, single group), allocation ratio, and | |
| 40 | | | framework (eg, superiority, equivalence, non-inferiority, | |
| 41 | | | exploratory) | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | Methods: | | | |
| 46 | Participants, | | | |
| 47 | interventions, and | | | |
| 48 | outcomes | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Study setting | #9 | Description of study settings (eg, community clinic, academic | 5 |
| 52 | | | hospital) and list of countries where data will be collected. | |
| 53 | | | Reference to where list of study sites can be obtained | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 6 |
| 58 | | | eligibility criteria for study centres and individuals who will | |
| 59 | | | | |
| 60 | | | | |

| | | | |
|---|----------------------|--|-----|
| | | perform the interventions (eg, surgeons, psychotherapists) | |
| Interventions: description | #11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered | 10 |
| Interventions: modifications | #11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease) | n/a |
| Interventions: adherence | #11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests) | n/a |
| Interventions: concomitant care | #11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | 6 |
| Outcomes | #12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | 7-9 |
| Participant timeline | #13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | 7 |
| Sample size | #14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | 12 |
| Recruitment | #15 | Strategies for achieving adequate participant enrolment to reach target sample size | 5 |
| Methods: Assignment of interventions (for controlled trials) | | | |
| Allocation: sequence generation | #16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | n/a |

| | | | | |
|----|------------------------|----------------------|--|---------|
| 1 | Allocation concealment | #16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | n/a |
| 2 | mechanism | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | 5-6 |
| 9 | implementation | | | |
| 10 | | | | |
| 11 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | n/a |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | n/a |
| 18 | emergency unblinding | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Methods: Data | | | |
| 23 | collection, | | | |
| 24 | management, and | | | |
| 25 | analysis | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | 7-9; 11 |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | Data collection plan: | #18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | n/a |
| 40 | retention | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | Data management | #19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | 12 |
| 45 | | | | |
| 46 | | | | |
| 47 | | | | |
| 48 | | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | 13 |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | n/a |
| 57 | analyses | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------------|----------------------|---|-----|
| 1 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non- | n/a |
| 2 | population and missing | | adherence (eg, as randomised analysis), and any statistical methods | |
| 3 | data | | to handle missing data (eg, multiple imputation) | |
| 4 | | | | |
| 5 | | | | |
| 6 | Methods: Monitoring | | | |
| 7 | | | | |
| 8 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary of its | 11 |
| 9 | formal committee | | role and reporting structure; statement of whether it is independent | |
| 10 | | | from the sponsor and competing interests; and reference to where | |
| 11 | | | further details about its charter can be found, if not in the protocol. | |
| 12 | | | Alternatively, an explanation of why a DMC is not needed | |
| 13 | | | | |
| 14 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 13 |
| 15 | interim analysis | | including who will have access to these interim results and make | |
| 16 | | | the final decision to terminate the trial | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Harms | #22 | Plans for collecting, assessing, reporting, and managing solicited | 10 |
| 23 | | | and spontaneously reported adverse events and other unintended | |
| 24 | | | effects of trial interventions or trial conduct | |
| 25 | | | | |
| 26 | | | | |
| 27 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, and | 11 |
| 28 | | | whether the process will be independent from investigators and the | |
| 29 | | | sponsor | |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | Ethics and | | | |
| 34 | dissemination | | | |
| 35 | | | | |
| 36 | Research ethics | #24 | Plans for seeking research ethics committee / institutional review | 13 |
| 37 | approval | | board (REC / IRB) approval | |
| 38 | | | | |
| 39 | | | | |
| 40 | Protocol amendments | #25 | Plans for communicating important protocol modifications (eg, | 13 |
| 41 | | | changes to eligibility criteria, outcomes, analyses) to relevant | |
| 42 | | | parties (eg, investigators, REC / IRBs, trial participants, trial | |
| 43 | | | registries, journals, regulators) | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |
| 47 | Consent or assent | #26a | Who will obtain informed consent or assent from potential trial | 6 |
| 48 | | | participants or authorised surrogates, and how (see Item 32) | |
| 49 | | | | |
| 50 | | | | |
| 51 | Consent or assent: | #26b | Additional consent provisions for collection and use of participant | n/a |
| 52 | ancillary studies | | data and biological specimens in ancillary studies, if applicable | |
| 53 | | | | |
| 54 | | | | |
| 55 | Confidentiality | #27 | How personal information about potential and enrolled participants | 6 |
| 56 | | | will be collected, shared, and maintained in order to protect | |
| 57 | | | confidentiality before, during, and after the trial | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|---|----------------------|---|-------|
| 1 | Declaration of interests | #28 | Financial and other competing interests for principal investigators for the overall trial and each study site | 19 |
| 2 | | | | |
| 3 | | | | |
| 4 | Data access | #29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | 12 |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Ancillary and post trial care | #30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | n/a |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | Dissemination policy: trial results | #31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | 13-14 |
| 15 | | | | |
| 16 | | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | Dissemination policy: authorship | #31b | Authorship eligibility guidelines and any intended use of professional writers | 19 |
| 22 | | | | |
| 23 | | | | |
| 24 | Dissemination policy: reproducible research | #31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | n/a |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Appendices | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Informed consent materials | #32 | Model consent form and other related documentation given to participants and authorised surrogates | n/a |
| 32 | | | | |
| 33 | | | | |
| 34 | Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | n/a |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |

40 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons
 41 Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a
 42 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59

BMJ Open

Study design and protocol of a low to high intensity computer-based cognitive training at home in supplement to standard care in patients with AD

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2021-050993.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 17-May-2022 |
| Complete List of Authors: | Dimachki, Samar; Université Lyon 2, Laboratoire d'Etude des Mécanismes Cognitifs Tarpin-Bernard, Franck; Université Grenoble Alpes UFR Informatique Mathématiques et Mathématiques Appliquées de Grenoble, Laboratoire d'informatique de Grenoble Croisile, Bernard; Hospices Civils de Lyon, Neurology Hospital - Neuropsychology Department Chainay, Hanna; Université Lumière Lyon 2, EMC Laboratory - (Etudes des Mécanismes Cognitifs) |
| Primary Subject Heading: | Rehabilitation medicine |
| Secondary Subject Heading: | Geriatric medicine, Neurology, Mental health, Medical management |
| Keywords: | GERIATRIC MEDICINE, Dementia < NEUROLOGY, MENTAL HEALTH, PREVENTIVE MEDICINE, Delirium & cognitive disorders < PSYCHIATRY, COMPLEMENTARY MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3 1
4
5 2
6
7 3 **Study design and protocol of a low to high intensity computer-based**
8
9 4 **cognitive training at home in supplement to standard care in patients with AD**
10
11
12 5
13
14 6
15
16 7
17
18 8

19 9 Samar Dimachki^{1,3}, Franck Tarpin-Bernard³, Bernard Croisile^{2,3} & Hanna Chainay¹
20
21 10
22
23 11

24
25 12 ¹Laboratoire d'Étude des Mécanismes Cognitifs, Université Lyon 2, Bron, France
26

27 13 ² Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital
28 Neurologique, Bron, France
29 14

30
31 15 ³Scientific Brain Training SA, Lyon, France
32

33
34 16 samar.dimachki@univ-lyon2.fr

35 17 f.tarpin@humansmatter.co

36
37 18 bernard.croisile@wanadoo.fr

38
39 19 hanna.chainay@univ-lyon2.fr
40

41
42 20
43 21 Corresponding author: Samar Dimachki

44 22 Université Lyon 2

45 23 Laboratoire d'Étude des Mécanismes Cognitifs

46
47 24 5 avenue Pierre Mendès France

48
49 25 69676 Bron, France

50
51 26 E-mail : samar.dimachki@univ-lyon2.fr

52 27 **Words count: 7588**

53
54 28 **Without references: 5765**

55
56 29 **References: 1721**
57
58
59 30
60 31

1
2
3 32 **Abstract**

4 33 **Introduction:** Recent studies on cognitive training in patients with Alzheimer's disease (AD) showed
5 34 positive long-term effects on cognition and daily living, suggesting remote computer-based
6 35 programmes to increase training sessions while reducing patient's travelling. The aim of this study is
7 36 to examine short- and long-term benefits of computer-based cognitive training at home in patients
8 37 with mild to moderate AD, as a complement to the training in speech and language therapists' (SLT)
9 38 offices. The secondary purpose is to study training frequency required to obtain noticeable effects.

10 39 **Methods and analyses:** This is a national multi-centre study, conducted in SLT offices. The patients
11 40 follow training in one of three conditions: once a week in SLT office only (regular condition) and once
12 41 a week in SLT office plus one or three times per week at home. The trainings' content in SLT office and
13 42 at home is identical. For all three groups near and far transfer will be compared to evaluate training
14 43 frequency's effect. Our primary outcome is executive and working memory scores in experimental
15 44 tasks, and the secondary is neuropsychological tests and questionnaires' scores. Linear models'
16 45 analyses are considered for all measures with a random intercept for patients and another for per
17 46 practice. The fixed effects will be: three modality Groups and Time, repeated measures, (T0- pre-
18 47 training, T1 - post-training, T2 - long-term follow-up) and the interaction pairs.

19 48
20 49 **Ethics and dissemination:** The study got ethics approval of the national ethical committee CPP Sud
21 50 Méditerranée III (Nr. 2019-A00458-49) and of the National Commission for Information Technology
22 51 and Liberties (Nr. 919217). Informed consent is obtained from each participant. Results will be
23 52 disseminated in oral communications or posters in international conferences and published in
24 53 scientific journals.

25 54 **Trial registration number:** ClinicalTrials.gov identifier (NCT04010175).

26 55 **Keywords:** Alzheimer's disease, MCI, computer-based cognitive training, at home cognitive training,
27 56 cognitive benefits, quality of life

28 57

29 58

30 59

31 60

32 61

33 62

1
2
3 63 **Strengths and limitations of the study**
4

5 64 ► This study will provide information on the short- and long-term effects of remote computer-based
6 cognitive training in addition to regular training in SLT office for patients with AD.
7

8 65
9 66 ► This study will shed light on the optimal cognitive training frequency to be administered.

10 67 ► This study will evaluate the adherence to the computer-based programme at home compared to
11 training conducted exclusively in the SLT's office, as this factor is likely to be favourable to the
12 adherence given the reduction in travel and training in a familiar environment.
13

14 69
15 70 ► The limitation of the present study is that it will not control for the familiarity of the patients with
16 AD with the computer tool, nor for their degree of autonomy in completing remote training by
17 themselves.
18
19 72

20
21 73
22

23 74
24

25 75
26

27 76
28

29 77
30

31 78
32

33 79
34

35 80
36

37 81
38

39 82
40

41 83
42

43 84
44

45 85
46

47 86
48

49 87
50

51 88
52

53 89
54

55
56
57
58
59
60

90 INTRODUCTION

91 Considering increasing occurrence of neurodegenerative disorders in the older adults, such as
92 Alzheimer's disease (AD), and in the absence of effective drug treatment, cognitive training appears to
93 be a promising alternative in healthy and pathological aging for improving cognitive functioning [1-3]
94 and quality of life [4-5]. For some researchers cognitive training is also an added value to drug
95 treatment, as it has been observed to enhance the expression of drug effects [6].

96 The efficacy of cognitive training in patients with AD is still under the debate [8], especially
97 regarding the best methodological approaches to optimize the training outcomes [9-10], including
98 training feasibility, patient commitment, and motivation. The computer-based cognitive training
99 (CBCT) seems to have several advantages as it provides wide variety of well-calibrated exercises and
100 allows, for example, to easily adapt their difficulty to each patient [11]. The short- and long-term
101 benefits of CBCT were first shown in healthy older adults [7,12,13], but have also been proven in
102 patients with AD and MCI [14-18].

103 Several studies have highlighted the importance of some criteria that are essential for successful
104 training, whatever its type [19, 15, 20]. Overall, studies recommend early intervention with sessions
105 between 30 minutes and 1 hour and session's frequency of several times a week [9-10, 21]. Such a
106 design is supposed to maintain strong commitment and motivation throughout the training, which is
107 essential for its effectiveness. However, these recommendations face some important problems that
108 make their application difficult. First, few people are concerned about small changes in performance,
109 the majority will only consult when symptoms become more pronounced, which prevents the early
110 intervention suggested by several authors [21-25]. Second, involving patients in high-frequency
111 cognitive training protocols faces several difficulties, the most important of which is frequent travel
112 between home and speech and language therapist's office (SLT). As the disease progresses, autonomy
113 is compromised, and the need of a caregiver's assistance is an additional difficulty. In addition, the
114 change of seasons brings many health problems that interfere with training and often lead to
115 interruptions. One way of circumventing these problems would be to offer a CBCT including some
116 sessions at home [26,17]. Our main hypothesis is that remote cognitive training using computer-based
117 programmes is an effective way to increase the cognitive and psychological benefits of training as an
118 outcome of training. We also hypothesized that more frequent training (e.g., several times per week)
119 should bring greater benefits than training performed once a week.

120

121 The primary objective of the present study is to examine the short- and long-term benefits of
122 at home CBCT as a complement to in-office CBCT in patients with mild to moderate AD. The secondary

1
2
3 123 objective is to evaluate the best frequency of the at home training. To do this, we administer computer-
4 124 based cognitive training for 4 months under three conditions: (1) in SLT's office once a week, (2) in
5 125 SLT's office once a week plus once at home, and (3) in SLT's office once a week plus three times at
6 126 home.
7
8
9

10 127

11 128

12 129 **Method**

13 130

14 131 **1. Design**

15 132 This is an experimental study with minimal risks, with 3 parallel groups, namely the training group at
16 133 the SLT's office only (REG – regular group), the group at the SLT's office plus one session per week at
17 134 home (MFG - moderate frequency group) and the group at the SLT's office plus three session per week
18 135 at home (HFG – high frequency group). Patients will be included for 2 years, starting on 1st September
19 136 2020 and ending 1st September 2022. For each participant, the inclusion period is approximately 8
20 137 months. During this period, participants cannot be included in other protocols that may influence their
21 138 cognitive or emotional functions. Patients and their caregivers are informed of this point before signing
22 139 the informed consent and the SLTs are asked to monitor them throughout the protocol. The total
23 140 duration of the study is 32 months. All inclusions and testing will be carried out in SLT offices. The
24 141 training will be done in SLT offices and at patients' homes (see Figure 1 for a study design). The content
25 142 of the training in SLT office and at home is identical.

26 143 This study obtained the authorization of the national ethical committee CPP Sud Méditerranée III (Nr.
27 144 2019-A00458-49, version 5 from 18/11/2019) and of the National Commission for Information
28 145 Technology and Liberties (Nr. 919217) and was registered on clinicaltrials.gov (NCT04010175).

29 146 **1.1 Patient and Public Involvement:**

30 147 patient and public were not involved.
31
32
33
34
35
36
37
38

39 148

40 149

41 150 Figure 1: illustrating on the time axis the evolution of the experiment with the facts marked on a weekly basis
42 151 trainings take place between the 2nd and the 17th week for the 3 training groups simultaneously. Note: V = Visit;
43 152 W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency group; MHG =
44 153 moderate frequency group.
45
46
47
48
49
50
51
52
53

54 154

1
2
3 155 **2. Participants**
4

5
6 156 This study concerns people 60 years or older with a diagnosis of prodromal to moderate Alzheimer's
7
8 157 disease. To recruit participants, we contacted SLTs subscribers to SBT's Happyneuron Pro digital tools
9
10 158 through the SBT Humans Matter company network. They first answered a questionnaire to identify
11
12 159 SLTs practicing with patients with AD. These SLT received a letter of invitation to participate in our
13
14 160 study. Eventually, 27 SLTs from different regions of France joined the study and become clinical
15
16 161 investigation centres (CIS). A complete list of these SLTs can be obtained from the Department of
17
18 162 Clinical Research and Innovation of the Hospices Civils of Lyon¹. Each SLT is responsible for presenting
19
20 163 the study in his or her office to patients whose profile matches our inclusion criteria (for details on
21
22 164 eligibility criteria see Box 1). Interested patients will receive the information and consent leaflets. At
23
24 165 the next visit, they are asked if they wish to participate to the study, and if so, they sign the informed
25
26 166 consent. Thus, the patients are included by the SLTs who also sign an informed consent after validation
27
28 167 by the neurologist, the Principal Investigator of this study. Patients are informed that during the study
29
30 168 they cannot take part in any other study that could potentially have an effect on their cognitive
31
32 169 functions.
33

34 170

35 171

36 172

37 173

38 174 **2.1 Eligibility**

39 175 The eligibility criteria are presented in Box 1.

40 **Box 1. Eligibility criteria**

41 **Inclusion criteria:**

- 42 1. Age \geq 60 years
- 43 2. Native French speaker
- 44 3. Diagnosis of Alzheimer's disease according to the DSM V criteria
- 45 4. Mild to moderate cognitive impairment as stage of disease progression (Mini-Mental State Examination score superior to 15)
- 46 5. Unchanged psychotropic treatment in the month prior to inclusion
- 47 6. Signed informed consent for a participation to the study (personally or by a legal representative)

48 **Exclusion criteria:**

- 49 1. Uncorrected vision or hearing impairments
- 50 2. Motor dysfunction symptoms that could prevent the tests from being carried out
- 51 3. Not having a computer preventing cognitive training at home
- 52 4. Receiving SLT care for more than 3 months
- 53 5. Refusal to participate in the study
- 54 6. Being under guardianship or curatorship

55
56
57
58
59
60
¹ Direction de la Recherche Clinique, Hospice Civil de Lyon
3, quai des Célestins, 69229 Lyon Cedex 2

176

2.2 Withdrawal Criteria

Each patient is free to withdraw from the study at any time without giving reasons, simply by informing one of the investigators. In case of withdrawn of consent, the data collected up to the date of withdrawal will be analysed.

181

3. Randomization and Pseudonymization Method

To avoid any unequal treatment of patients in the same SLT, we decided to randomize SLTs' offices into different training groups, instead of randomizing the patients. Thus, each office will be assigned to one of the training groups and all patients included in that SLT office will follow the same training procedure (REG, MFG or HFG). Offices will be allocated to each group in a balanced way in terms of socio-demographic considerations, depending on their geographical location. This allocation will be done by a manager from the SBT Research & Development department before the study beginning. If, despite randomization, an imbalance occurs within groups due to inter-individual differences such as age, gender, education and disease severity, these factors will be considered as covariates in the analysis of results.

Each patient will receive a pseudonymized number consisting of, in order, of the number of the investigating centre, the inclusion number for this centre and the patient's initials. The SLT will keep the table of correspondence between this number and the first and last name, as well as the address and telephone number for all patients included in his/her centre.

196

4. Procedure

Our study follows a conventional protocol used to evaluate the cognitive and psychological benefits of cognitive training (for a review, [27]) (see Figure 1 and Table 1 for details). Each patient will be seen 21 times (Visit 1 to Visit 21). The content of each visit is described here below. Prior to inclusion, patients likely to take part in the study will be identified in the SLT offices as part of their regular care. They will be informed by the speech and language therapist, co-investigator, about the study. The patient will be given any explanation necessary for a good understanding of the study, as well as an information letter explaining the objectives and the course of the protocol. The speech and language therapist will also give the patient a consent form in duplicate. The patient will have one week to decide whether to take part in the study.

207

208 Inclusion visit - V1

1
2
3 209 If the patient agrees to take part in the study, the volunteer and the SLT (by delegation) will date and
4
5 210 sign two copies of the consent form (one will be kept by the patient, the other will be kept by the SLT).

6
7 211

8 212 Assessment visit: pre-training - V2

9
10 213 During this visit, patients will undergo a series of experimental tasks, neuropsychological tests and
11
12 214 questionnaires that will serve as a baseline for our primary and secondary outcomes measures of
13
14 215 training effectiveness.

15
16 216

17 217 Training visits - V3 to V19

18 218 Visits 3 to 19 will be devoted to training. These visits will be carried out at a frequency of once a week,
19
20 219 preferably on fixed days +/- 1 day. The patient will perform a series of short training exercises involving
21
22 220 memory, executive functions, processing speed, visuospatial abilities for approximately 45 minutes
23
24 221 using the Happyneuron Professional software (<https://www.happyneuronpro.com>). The number and
25
26 222 nature of the training sessions will be identical for all participants. However, the difficulty will be
27
28 223 adapted automatically by the software according to the patient's performance. Patients and their
29
30 224 caregivers will be asked not to perform the cognitive exercises outside of training and the SLTs will be
31
32 225 asked to monitor this throughout the protocol.

33 226 For all groups the SLT will, if possible, designate a fixed day of the week for in-office training. If the
34
35 227 patient misses this day, it will be rescheduled, if possible, to another day of the same week. For the
36
37 228 HFG and MFG groups which are to train at home, the SLT will schedule the day(s) for trainings at home
38
39 229 and patients and their caregivers will receive the e-mail on the morning of the training day. If, despite
40
41 230 of this, patient forgets to train they will be allowed to train another day of the week. The SLT will be
42
43 231 able to check whether or not the patient has trained on the scheduled day and, if necessary, will
44
45 232 contact patient or his/her caregiver to reschedule the training for the next day. Patients will be also
46
47 233 informed that they can ask the caregiver to solve for a technical problem or to call his/her SLT.

48
49 234

50 235 Assessment visit: post-training - V20

51
52 236 During this visit, the patients will complete the same assessments as during the pre-training. This will
53
54 237 allow comparison of the effectiveness of the training in the three training conditions within and
55
56 238 between groups.

57
58 239

59 240 Assessment visit: long-term follow-up - V21

60 241 During this visit, the patients will complete the same assessments as in the pre-training and post-
242 training visits. This will allow for intra- and inter-group comparisons of the sustainability of the training
243 effectiveness.

244

245

Table 1. The main steps of the protocol process with the timetable.

| Steps | V0 Pre- inclusion | V1 Inclusion | V2 Assessment T0 | V3 to V19 Training | V20 Assessment T1 | V21 Assessment T2 |
|---|-------------------------|-----------------|------------------------|-----------------------|-------------------------|-------------------------|
| Time | D-30 à D-15 | D0 | W1 | W2-W17 | W18 | W30 |
| Allocation | X | | | | | |
| Eligibility screen | X | | | | | |
| Study presentation to the patient | X | | | | | |
| Signature of the informed consent | | X | | | | |
| Assessments (Neuropsychological tests, questionnaires and experimental tasks) | | | X | | X | X |
| Cognitive training | | | | | | |
| Group REG | | | | X | | |
| Group HFG | | | | X | | |
| Group MFG | | | | X | | |
| Collection of adverse events | | | X | X | X | X |

246 Note: V = Visit; W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency
 247 group; MHG = moderate frequency group.

248

249 5. Primary measures of training benefits

250 In order to test the effects of the training, we will use three types of objective measures: experimental
 251 tasks, neuropsychological tests, and questionnaires. Our primary outcome measures are the scores
 252 that patients with AD will obtain in executive and working memory experimental tasks. Our secondary
 253 outcome measures are the scores that patients will obtain on neuropsychological tests and
 254 questionnaires that will provide information on the overall level of improvement and, more
 255 importantly, answers on the effect of training on well-being and self-esteem. We will calculate the
 256 composite scores for our primary outcome measures. All measures will be taken at the three time-
 257 points (T0 – pre-training, T1 – immediately after training, and T2 – 3 months after training). The choice
 258 of these measures was made according to the cognitive functions trained and the cognitive (working
 259 memory, executive functions) and psychological (self-esteem, motivation, psychological state -
 260 depression/anxiety, assessment of quality of life) domains for which training benefits are expected.
 261 These assessments allow us to, first, determine the baseline level of the patient's cognitive abilities
 262 and their emotional and motivational state and, second, to measure the benefit of training by

1
2
3 263 comparing the pre-training results (T0) with those obtained immediately after the end of the training
4 264 (T1) and 3 months later (T2).

5
6 265
7

8 9 266 **5.1 Neuropsychological tests**

10 11 267 *Verbal Fluency [28]*

12
13 268 The general aim of the fluency test is to assess executive functions by evaluating patient's ability to
14 269 access their lexical repertoire in relation to a given letter or a semantic category.

15 16 17 270 *TMT A/B [29]*

18 271 Trail Making Test consists of two parts. Part A measures processing speed – the patient must connect
19 272 in ascending order the 25 numbers randomly distributed in circles on page A4. Part B measures
20 273 cognitive flexibility – the patient has to perform the same task as in part A while alternating numbers
21 274 and letters (i.e., 1-A-2-B-3-C, etc.).

22 23 24 25 275 *Logical Memory [30]*

26 276 Logical Memory I and II are subtests of the *Wechsler MEM IV*. Each correctly recalled detail out of 25
27 277 details per story is scored 1 point, giving the maximum raw score of 50 points for two stories. Logical
28 278 Memory II is a delayed condition of Logical Memory I. The test ends with recognition, in which patient
29 279 must answer a series of questions about each story.

30
31
32
33
34 280

35 36 37 281 *MMSE [31]*

38 282 The Mini Mental State Examination (MMSE) is a commonly used test for screening general cognitive
39 283 impairment. The maximum score of the MMSE is 30 points.

40 41 42 284 *Digit Span [30]*

43 285 Two types of spans are used, forward and backward, to measure short-term and working memory
44 286 respectively. In both cases, the test ends if the participant fails to repeat two consecutive series. The
45 287 maximum score is 48 points.

46
47
48
49 288

50 51 289 **5.2 Questionnaires**

52 290

53 54 291 *Geriatric Depression Scale (GDS) 30 items [32]*

55 292 The GDS is 30 item self-reported scale that uses "Yes/No" responses. It is used to detect the symptoms
56 293 of depression in older adults. Scores of 0 to 4 are considered normal, 5 to 8 indicate mild depression,
57 294 9 to 11 moderate depression and 12 to 15 severe depression.

58
59
60

1
2
3 295 *Questionnaire of Cognitive Complaint [33]*

4
5 296 This is a 10-question yes/no questionnaire covering memory, language, orientation and behavior,
6
7 297 allowing clinicians to distinguish a mild cognitive complaint from an at-risk one.

8 298 *Instrumental Activities of Daily Living (IADL) [34]*

9
10 299 Eight domains of daily functioning are measured with the IADL scale, with scores ranging from 0
11
12 300 (dependent) to 8 (independent) for women and from 0 to 5 for men.

13 301 *Pittsburgh Sleep Quality Index (PSQI) [35]*

14
15 302 It is used to measure quality and sleep cycles in older adults by assessing seven sleep domains. It is a
16
17 303 self-reported measure giving a global score ranging from 0 (no difficulties) to 21 (severe difficulties),
18
19 304 with scores above 5 reflecting disturbances of sleep and sleep quality.

20 305 *SF 12 [36]*

21
22 306 This is a 12-question self-reported survey assessing the quality of life and more specifically the impact
23
24 307 of health condition on daily life by exploring 8 domains. Two scores are calculated – a mental
25
26 308 component score (MCS-12) and a physical component score (PCS-12).

27 309 *Motivation scale for older adults [37]*

28
29 310 This scale measures intrinsic motivation, self-determined and non-self-determined extrinsic
30
31 311 motivation and amotivation in different life contexts. There are 12 motivational statements per life
32
33 312 context. Each of these statements is rated on a scale of 1 to 7 points.

34 313

35 314

36
37
38 315 **5.3 Experimental Tasks**

39
40 316 Four experimental tasks were constructed to measure the near transfer of training effects on executive
41
42 317 functions and memory, the cognitive functions targeted by the training.

43
44 318 *Stop Signal [38]*

45
46 319 This task evaluates inhibition skills. The participant is asked to give a response to the presentation of a
47
48 320 target stimulus (Go signal) and to prevent this response when the stimulus is followed or preceded by
49
50 321 a sound signal (Stop signal). The task consists of two phases. The mean reaction time for each
51
52 322 participant is calculated to be used in a second phase as a reference time for the presentation of the
53
54 323 auditory signal. In total, there are 96 trials. The trials are presented randomly. The presentation of the
55
56 324 auditory signal is adaptive. The first signal is presented after the stimulus at reference time calculated
57
58 325 in the phase 1. Each subsequent signal is presented according to the participant's ability to withhold
59
60 326 the response. If the participant succeeds, the time is increased by 10ms, if the participant fails, the
327 time is decreased by 10ms.

1
2
3 328 *Letter and number pairs [39]*

4
5 329 This task is used to assess mental flexibility. The participant sees 4 blocks of 48 letter-number pairs,
6
7 330 i.e. a total of 192 randomly presented trials. Each pair appears for 350 ms on a computer screen, either
8
9 331 in a square located in the upper part of the screen or in a square located in the lower part of the screen.
10 332 The participant is asked to judge the parity if the pair appears at the upper part of the screen, and to
11 333 make consonant/vowel judgement if it appears at the lower part of the screen. Reaction time and
12 334 accuracy are recorded.

13
14
15 335 *Up-dating span [39]*

16
17 336 This task is used to assess the updating in working memory. Series of letters appear on a computer
18
19 337 screen, the participant is asked to memorize the last three letters presented, without knowing the
20
21 338 length of the series. The series are presented in random order. Reaction time and accuracy are
22 339 recorded.

23
24
25 340 *Operation reading letters span [40]*

26 341 This task is used to assess working memory. It consists of 8 series of 2 to 5 letters. The letters are
27
28 342 separated by a presentation of one, two or three operands consisting of one or two numbers. The
29
30 343 participant is asked to memorize each series of letters while reading aloud between each letter the
31
32 344 operations and their results. At the end of the series, the participant is asked to recall the letters in the
33 345 order of their presentation.

34
35 346

36
37 347 **6. Computer-based cognitive training**

38
39
40 348 The training will be done for each participant over a period of 4 months on the PC using the
41
42 349 Happyneuron Pro software (<https://www.scientificbraintrainingpro.fr>). Patients will complete the
43
44 350 training as described in Design section, page 5. At the beginning of each session, the SLT will ask the
45
46 351 participant to report any event that have occurred during the week that may, in any way, disturb
47
48 352 his/her participation in the training. These events will be reported in the EON. The rationale for a 4-
49
50 353 month training period is that we wish to evaluate the benefits of a relatively short period of time that
51
52 354 would be less prone to drop-out and that is of sufficient duration, according to the literature, to
53
54 355 produce benefits [41 - 42]. We choose the training tool, Happyneuron Pro², because it is a well-known
55
56 356 cognitive remediation product frequently used by the SLTs in France, and in particular by the SLTs
57
58 357 participating in our study. Research and clinical studies have shown the effectiveness of the training

59
60

² Happyneuron Pro is a product developed by Scientific Brain Training.

358 programmes proposed in Happyneuron Pro software to improve cognitive functioning in patients
 359 suffering from different diseases and in normal aging [43 - 48]

360 Each training session lasts approximately 45 minutes and consists of 10 exercises of varying lengths,
 361 but not exceeding 4 minutes (see Table 2 for details). The training programme stops automatically
 362 after 45 minutes, even if the patient has not completed the 10 exercises planned for the session.
 363 However, the session stops after the patient has completed the exercise in hand. Patients are not
 364 informed how many exercises they will perform in each session, only that each session will last
 365 approximately 45 minutes. The training is adaptable from session to session. Thus, each session starts
 366 with the exercise and the level that the previous session ended with. Each exercise has 9 levels of
 367 difficulty, and each level is displayed at least twice. The criterion for moving up to a higher level of
 368 difficulty is to successfully perform the current level twice in a row.

369 The training targets the following cognitive functions: working and short-term memory, executive
 370 functions, visuo-spatial abilities, and processing speed (see Table 2 for more details).

371

372 Table 2. Exercises included in cognitive training and cognitive capacity targeted by the exercise.

| Game type | Cognitive capacity targeted by the exercise |
|-------------------------------------|--|
| 1- Tower of Hanoi | - Problem solving |
| 2- Put some order in these accounts | - Visuospatial exploration - Attention and numerical processing |
| 3- Bird songs | - Auditory memory - Memorizing strategies |
| 4- Objects, where are you? | - Visuospatial memory - Binding capacities |
| 5- Find your way back. | - Visual short-term memory - Working memory |
| 6- Blazon Game | - Visual memory - Attention - Visuospatial perception |
| 7- Waiter please | - Verbal memory - Visual memory - Mental rotation ability |
| 8- Conduct the investigation | - Lexical comprehension - Categorization skills |
| 9- It is up to you to count | - Working memory - Mental arithmetic |
| 10- You have got a message | - Verbal-auditory memory |

373

374 7. Equipment and programming

375 The SLT's office and patient's personal computers are the only equipment used to run our protocol. All
 376 questionnaires and neuropsychological tests (except TMT and Figure from MMSE) were digitalized on

1
2
3 377 Typeform. The experimental tasks were designed and programmed on the Open Sesame free access
4
5 378 software (Version 3.2.5). This software was therefore installed on the SLT's computers. The training
6
7 379 sessions were programmed on Happyneuron Pro Platform <https://www.scientificbraintrainingpro.fr/>
8

9 380

10 381 **8. Study Management**

11 382

12 383 **8.1 General management**

13
14
15 384 Each SLT participating in the study received an appropriate training in the use of all tools needed to
16
17 385 carry out the protocol. The training was provided in small groups or individually videoconferences and
18
19 386 complemented by e-mail exchanges and video tutorials, a digital user guide, and power point
20
21 387 presentations.
22

23 388

24
25 389 Each SLT has two personal password-protected areas, one on the Happyneuron Pro platform to
26
27 390 manage the training and another one on the Ennov Clinical containing the patients' electronic
28
29 391 observation notebooks (EON) to store all clinical information and results of neuropsychological tests
30
31 392 and experimental tasks for each patient. It is hosted on the secure platform of the *Hospices Civils de*
32
33 393 *Lyon* (HCL). These personal areas are supervised by principal investigator, junior investigator of this
34
35 394 study, and a clinical research assistant from the HCL.

36 395

37 396 The workspace on Happyneuron Pro platform is used to create the training area for each included
38
39 397 patient and to specify the weekly frequency and the days of training sessions, depending on the
40
41 398 training group. Once the patient's space is created and the sessions scheduled, the patient receives a
42
43 399 link by email on the scheduled days and all he /she has to do to access the training, is to click on the
44
45 400 link.

46 401

47 402 The study is monitored by the Clinical Research and Innovation Department of the Hospices Civils of
48
49 403 Lyon³. A designed clinical research assistant is in charge of the monitoring which includes:

50 404 - a study start-up visit to the coordinating centre and the inclusion centres,

51 405 - a mid-term visit

52 406 - a closing visit

53 407 At the mid-term and closing visits, the consent forms and EON will be checked.

54 408
55
56
57
58
59
60

³ HCL's identification code for the study 69HCL18_0881

1
2
3 409 The coordinating centre is composed of the three investigators (principal, senior and junior
4 410 investigator) who designed the protocol and will be in charge of verification of the inclusion/exclusion
5 411 criteria prior to the inclusion of patients in the study and of the data analyses. These investigators are
6 412 not involved in data collection.
7
8
9

10 413

11 414 **8.2. Data management and storage**

12
13
14 415 The performance on the neuropsychological tests performed via Typeform is automatically recorded.
15 416 When completed, an email containing the patients' scores is automatically sent to the investigator and
16 417 the SLT, and patients' scores can be extracted from Typeform into Excel. Finally, the SLT enters the
17 418 scores of interest into the patient's EON.

18
19
20 419 Performances on the experimental tasks are recorded on the SLT's office computer and the scores of
21 420 interests are entered into the patient's EON.

22
23
24 421 The training results for each session are automatically stored on a secure server hosted by a health
25 422 data host. There is no transit between the servers, nor is there any storage of data on the patient's
26 423 computer. SLTs have the option of monitoring the trainings remotely: this is possible by accessing the
27 424 patient's space, which allows the SLTs to check whether the training has been carried out regularly and
28 425 to monitor patients' progress. If necessary, the SLTs can also access the results online.

29
30
31 426 All the data entered in EON are accessible during the inclusion period and after the end of the study
32 427 to the clinical research assistant in charge of the follow-up of the study and to the three investigators
33 428 in charge of the study and who are not involved in the data collection. Data extraction and analyses
34 429 are allowed at two points of the study, mid-term, and the end of inclusion period. The final trial dataset
35 430 that will be used for statistical analyses will be available to the three investigators in charge of this
36 431 study.
37
38
39
40
41
42

43 432

44 433 **9. Statistical considerations**

45 434 **9.1 Estimation of samples size**

46
47
48 435 The sample size per training group was estimated on the basis of previous protocols and literature
49 436 reviews [9, 49] which show that the number of patients included in the protocols varies between 15
50 437 and 150 per group. Taking into account the data of previous studies and expected size effect, we
51 438 decided to include 55 patients per group. Indeed, the size of each group was estimated to be 45,
52 439 assuming a small effect of the intervention (Cohen's $d = 0.40$), with a repeated measures factor Time
53 440 of assessment (pre-training, immediate post-training, long term post-training) and an independent
54 441 measures factor of Group (MFG, HFG, REG) to reach a power of 0.8 with an alpha at 0.05. We estimated

1
2
3 442 a 10% dropout of participants. Thus, we estimated the inclusion of 50 patients per group. In addition,
4 443 to consider the cluster randomization, we estimated that we need to increase our sample by 10%,
5 444 bringing the number of patients per group to 55. This number is compatible with our capacity to recruit
6 445 patients.
7
8
9

10 446 **9.2 Statistical methods description**

11
12
13 447 Linear models are considered for all behavioural measures collected with one random intercept per
14 448 patient and one per practice. The analysis will concern independent measures factor Group with three
15 449 modalities (MFG, HFG, REG) and repeated measures factor Time with three modalities (T0 - pre-
16 450 training, T1 - post-training, T2 - long term monitoring) and the interaction between these two factors.
17
18 451 The significance level is set at 0.05. In our longitudinal analysis, we risk floor, ceiling, and curvilinear
19 452 effects since we have stopped the inclusion at an MMSE score higher than 15. For this reason, we plan
20 453 to adjust the initial values first, and to avoid the biases linked to the adjustment, we will refer to the
21 454 DAG (Causal Directed Acyclic) Graph. We will then apply methods that take into account the floor and
22 455 curvilinear effects, by adjusting the mean value of the observations, and then through a linear mixed
23 456 model in a structural model we will study the evolution on the time axis and the common effects of
24 457 the co-variables.
25
26
27
28
29
30

31
32 458 The interim analyses are also planned, using the same models as described above, at three time points:
33 459 1 - after inclusion of 15 patients in each group, 2 - after inclusion of 30 patients in each group, and 3 -
34 460 after inclusion of 40 patients in each group. We decide to perform interim analyses to see if trends
35 461 would emerge on smaller samples than those estimated by the power analysis to be necessary to
36 462 obtain a training effect. These analyses are not intended to alter the protocol or planned inclusions.
37
38
39

40 463 Statistical analyses will be carried out using STATISTICA software.
41
42

43 464

44 465 **10. Risks and benefits**

45
46
47
48 466 There are no particular risks for patients to participate in this study. The only disadvantages could be
49 467 computer-related fatigue, especially for patients included in the HFG.
50

51
52 468 The major personal benefit for patients would be an improvement in their cognitive and emotional
53 469 state or a slowing of the progression of cognitive impairment. The secondary benefit could be the
54 470 improvement of their quality of life.
55

56
57
58 471 There is also a collective benefit since if the results of this study confirm our hypothesis, we could give
59 472 recommendations concerning at home training.
60

473

11. Ethics and dissemination

The study is conducted with the approval of the national ethics committee (CPP – *Comité de Protection des Personnes, Sud Méditerranée III*, Nr. 2019) and of the National Commission for Information Technology and Liberties (Nr. 919217). Any modification to the study design must be addressed to the clinical research assistant and if necessary, a request for modification must be addressed to the national ethical committee that issued the authorization for the study. The results of the study will be disseminated in the form of oral or posters presentations at international scientific conferences and seminars for health professionals (e.g., Alzheimer’s Association International Conference, *Union Nationale pour le Développement de la Recherche et de l’Evaluation en Orthophonie*) and published in a relevant scientific journal (e.g., *Journal of Alzheimer’s Disease*). The presentations are allowed after the first statistical analyses planned at the mid-point of inclusion.

12. Significance

Overall, this study will contribute to the knowledge of the effects of cognitive training on cognition in patients with AD in the prodromal to moderate stages. The comparison of results obtained for neuropsychological tests, questionnaires, and experimental tasks by REG patients with those obtained by MFG patients will inform about the effects of cognitive training at home carried out in addition to training in SLT office. This will provide clear indications about the usefulness of this type of cognitive training programme for patients with AD. The comparison of the results obtained by MFG patients with those obtained by HFG patients will provide indications as to the best frequency of training sessions needed.

Beyond the benefits of cognitive training on patients with AD cognition, and the importance of trying to determine the best frequency for optimal effects, other issues, which are independent of the cognitive training programme, may impact on its success if not carefully considered. AD has an important impact on autonomy, emotional balance and motivation, which are often linked to self-esteem [19-21]. Thus, it seems important, when designing cognitive training protocols for patients with AD to take into account psychological, environmental and autonomy factors for a more optimal cognitive training plan, which aims at the well-being of the individual as a whole [21,50-27]. Through the questionnaires administered in our protocol [32-37], we hope to shed light on the emotional benefits of training and answer questions regarding the engagement and adherence in patients with AD, as well as to provide a more informed opinion on the importance of seeking third-party help. Understanding whether the same issues of training independence arise for patients with mild and moderate AD will allow us to develop more accurate computer-based home training protocols for different patient profiles. These protocols should take into account the severity of cognitive decline

1
2
3 507 which may affect training autonomy as cognitive impairment increases. These considerations will allow
4
5 508 us to consider solutions for less autonomous people.
6
7 509
8
9 510
10
11 511
12
13 512
14
15 513
16
17 514
18
19 515
20
21 516

23 **Authors Contribution**

24
25
26 517 Author Contributions: Conceptualization, S.D. and H.C.; Data treatment, S.D.; Project administration,
27
28 518 S.D. and H.C., Supervision, H.C., F.T-B., B.C.; Writing—Original draft, S.D. and H.C.; Writing—Review &
29
30 519 editing, S.D., H.C., F.T-B. and B.C. All authors have read and agreed to the submitted version of the
31
32 520 manuscript.
33
34 521

35 **Fundings**

36
37
38 523 The funding for this study is provided by SBT Humans Matter Company and Laboratoire d'Etude des
39
40 524 Mécanismes Cognitifs (Université Lyon 2) within a framework of the CIFRE (*Convention Industrielle de*
41
42 525 *Formation par la Recherche* – Industrial Agreement for Training through Research) doctoral thesis
43
44 526 financed by ANRT French agency.

45 **Competing interests' statement**

46
47
48 528 Franck Tarpin-Bernard and Bernard Croisile are cofounders and shareholders of SBT Humans Matter.
49
50 529
51
52 530
53
54 531
55
56 532
57
58 533
59
60

1
2
3 534
4
5 535
6
7 536
8
9 537
10
11 538
12
13 539
14
15 540
16
17 541
18
19 542
20
21 543
22
23 544
24
25 545
26
27 546
28
29 547
30 548
31
32 549
33
34 550
35 551
36
37 552
38
39 553
40 554
41
42 555
43
44 556
45 557
46
47 558
48
49 559
50 560
51
52 561
53
54 562
55 563
56
57 564
58
59 565
60

References:

- [1] Cespón, J., Miniussi, C., Pellicciari, M.C. (2018). Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. *ScienceDirect Elsevier*, volume 43, 81-98. <https://doi.org/10.1016/j.arr.2018.03.001>
- [2] Günther, V. K., Schäfer, P., Holzner, B. J., & Kemmler, G. W. (2003). Long-term improvements in cognitive performance through computer-assisted cognitive training: a pilot study in a residential home for older people. *Aging & Mental Health*, 7(3), 200–206. <https://doi.org/10.1080/1360786031000101175>
- [3] Joubert, C., & Chainay, H. (2018). Aging brain: the effect of combined cognitive and physical training on cognition as compared to cognitive and physical training alone – a systematic review. *Clinical Interventions in Aging*, 13, 1267-1301. doi/10.2147/CIA.S165399
- [4] Chandler, M.J., Locke, D.E., Crook, J.E., et al., (2019). Comparative Effectiveness of Behavioral Interventions on Quality of Life for Older Adults With Mild Cognitive Impairment A Randomized Clinical Trial. *JAMA Network Open*. 2(5):e193016. doi:10.1001/jamanetworkopen.2019.3016
- [5] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation on the efficacy of strategic memory training in older adults: analysis of specific, transfer and maintenance effects. *Archives of Gerontology and Geriatrics*, 52(3), e192-197. <https://doi.org/10.1016/j.archger.2010.11.004>

- 1
2
3 566 [6] Requena, C., Maestú, F., Campo, P., Fernández, A., Otiz, T. (2006). Effects of cholinergic drugs and
4 567 cognitive training on dementia: 2-year follow-up. *Dementia and Geriatric Cognitive Disorders*,
5 568 22(4):339-345. DOI: 10.1159/000095600.
- 6
7
8 569 [7] Joubert, C. & Chainay, H. (2019). Effects of cognitive and aerobic training on working memory and
9 570 executive function in aging , a pseudo-randomised trial: Pilot study. *Journal of Ageing Research and*
10 571 *Healthcare*, 2(3), 46-70. Doi:10.14302/issn.2474_7785.jarh-18-2458.
- 11
12
13 572 [8] Kallio, E.L., Öhman, H., Kautiainen, H., Hietanen, Soini, H., Strandberg, T.E, Kautiainen, H., & Pitkälä,
14 573 K. (2018). Effects of Cognitive Training on Cognition and Quality of Life of Older Persons with
15 574 Dementia. *J Am Geriatr Soc*, 66: 664-670. <https://doi.org/10.1111/jgs.15196>
- 16
17
18 575 [9] Gates, N. J., & Sachdev, P. S. (2014). Is cognitive training an effective treatment for preclinical and
19 576 early Alzheimer's disease? *Journal of Alzheimer's Disease : JAD*, 42(Suppl), NaN-NaN.
20 577 <https://doi.org/10.3233/JAD-141302>
- 21
22
23 578 [10] Canu, E., Sarasso, E., Filippi, M., Agosta, F.(2018) Effects of pharmacological and
24 579 nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's
25 580 disease and mild cognitive impairment: a critical review. *Alzheimer's Research & Therapy* volume 10,
26 581 Article number: 21.
- 27
28
29 582 [11] Galante, E., Venturini, G., & Fiaccadori, C. (2007). Computer-based cognitive intervention for
30 583 dementia: preliminary results of a randomized clinical trial. *Giornale Italiano Di Medicina Del Lavoro*
31 584 *Ed Ergonomia*, 29(3 Suppl B), B26-32.
- 32
33
34 585 [12] Lampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older
35 586 adults: a systematic review and meta-analysis of effect modifiers. (2014). *PLoS Med*.
36 587 2014;11(11):e1001756. doi:10.1371/journal.pmed.1001756
- 37
38
39 588 [13] Klimova B. (2016). Computer-Based Cognitive Training in Aging. *Frontiers in aging neuroscience*, 8,
40 589 313. <https://doi.org/10.3389/fnagi.2016.00313>
- 41
42
43 590 [14] Klimova, B., & Maresova, P. (2017). Computer-based training programs for older people with mild
44 591 cognitive impairment and/or dementia. *Frontiers in Human Neuroscience*, 11, Article 262.
- 45
46
47 592 [15] Choi, J., & Twamley, E. W. (2013). Cognitive rehabilitation therapies for Alzheimer's disease: a
48 593 review of methods to improve treatment engagement and self-efficacy. *Neuropsychology*
49 594 *Review*, 23(1), 48–62. <https://doi.org/10.1007/s11065-013-9227-4>
- 50
51
52 595 [16] Cavallo, M., & Angilletta, C. (2019). Long lasting neuropsychological effects of a computerized
53 596 cognitive training in patients affected by early stage Alzheimer's disease: Are they stable over time?
54 597 *Journal of Applied Gerontology*, 38(7), 1035-1044. Doi: 10.1177/0733464817750276
- 55
56
57 598 [17] García-Casal, J.A., Loizeau, A., Csipke, E., Franco-Martín, M., Perea-Bartolomé, M.V., & Orrell, M.
58 599 (2017). Computer-based cognitive interventions for people living with dementia: a systematic
- 59
60

- 1
2
3 600 literature review and meta-analysis. *Aging and Mental Health*, 21(5), 454-467.
4
5 601 doi:10.1080/13607863.2015.1132677
6
7 602 [18] Shao YK, Mang J, Li PL, Wang J, Deng T, Xu ZX. Computer-Based Cognitive Programs for
8
9 603 Improvement of Memory, Processing Speed and Executive Function during Age-Related Cognitive
10
11 604 Decline: A Meta-Analysis. (2015). *PLoS One.*;10(6):e0130831. Published 2015 Jun 22.
12
13 605 doi:10.1371/journal.pone.0130831
14
15 606 [19] Carretti, B., Borella, E., Zavagnin, M., & De Beni, R. (2011). Impact of metacognition and motivation
16
17 607 on the efficacy of strategic memory training in older adults: analysis of specific, transfer and
18
19 608 maintenance effects. *Archives of Gerontology and Geriatrics*, 52(3), e192-197.
20
21 609 <https://doi.org/10.1016/j.archger.2010.11.004>
22
23 610 [20] Jaeggi, S. M., Buschkuhl, M., Shah, P., & Jonides, J. (2014). The role of individual differences in
24
25 611 cognitive training and transfer. *Memory & Cognition*, 42(3), 464-480. [https://doi.org/10.3758/s13421-](https://doi.org/10.3758/s13421-013-0364-z)
26
27 612 013-0364-z
28
29 613 [21] Hwang, H. R., Choi, S. H., Yoon, D. H., Yoon, B.-N., Suh, Y. J., Lee, D., Hong, C.-G. (2012). The Effect
30
31 614 of Cognitive Training in Patients with Mild Cognitive Impairment and Early Alzheimer's Disease: A
32
33 615 Preliminary Study. *Journal of Clinical Neurology*, 8(3), 190. <https://doi.org/10.3988/jcn.2012.8.3.190>
34
35 616 [22] Belleville, S., & Boller, B. (2016). Comprendre le stade compensatoire de la maladie d'Alzheimer
36
37 617 et agir pour promouvoir la cognition et la plasticité cérébrale. [Understanding the compensatory stage
38
39 618 of Alzheimer's disease and acting to promote cognition and cerebral plasticity.]. *Canadian Journal of*
40
41 619 *Experimental Psychology/Revue Canadienne de Psychologie Expérimentale*, 70(4), 288-294.
42
43 620 <https://doi.org/10.1037/cep0000087>
44
45 621 [23] Förster, S., Buschert, V. C., Teipel, S. J., Friese, U., Buchholz, H.-G., Drzezga, A., ... Buerger, K. (2011).
46
47 622 Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnesic MCI and
48
49 623 Mild Alzheimer's Disease. *Journal of Alzheimer's Disease*, 26(s3), 337-348.
50
51 624 <https://doi.org/10.3233/JAD-2011-0025>
52
53 625 [24] Mendoza Laiz, N., Del Valle Diaz, S., Rioja Collado, N., Gomez-Pilar, J., & Hornero, R. (2018).
54
55 626 Potential Benefits of a Cognitive Training Program in Mild Cognitive Impairment (MCI). *Restorative*
56
57 627 *Neurology and Neuroscience*, 36(2): 207-213.
58
59 628 <http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/RNN-170754>
60
61 629 [25] Clare L, Evans S, Parkinson C, Woods R, Linden D. (2004). Cognitive training and cognitive
62
63 630 rehabilitation for people with early-stage Alzheimer's disease: A review: Neuropsychological
64
65 631 Rehabilitation: Vol 14, No 4. Retrieved September 27, 2018,
66
67 632 from <https://www.tandfonline.com/doi/abs/10.1080/09602010443000074>
68
69 633 [26] Realdon, O., Rossetto, F., Nalin, M., et al. (2016). Technology-Enhanced Multi-Domain at Home
70
71 634 Continuum of Care Program with Respect to Usual Care for People with Cognitive Impairment: The

- 1
2
3 635 Ability-TelrehABILITation study protocol for an randomized controlled trial. *BMC Psychiatry*, 16(1), 425.
4
5 636 <https://www.ncbi.nlm.nih.gov/pubmed/27887597>
6
7 637 [27] Cruz, V. T., Pais, J., Bento, V., Mateus, C., Colunas, M., Alves, I., ... Rocha, N. P. (2013). A
8
9 638 Rehabilitation Tool Designed for Intensive Web-Based Cognitive Training: Description and Usability
10
11 639 Study. *JMIR Research Protocols*, 2(2). <https://doi.org/10.2196/resprot.2899>
12
13 640 [28] Croisile, B., Beaumont, C., Hadjedj, T., Riccio, J., & Astier, J.L. (2011). La Batterie
14
15 641 Neuropsychologique COurte (BANCO) : étalonnage chez 347 sujets normaux de 50 à 92 ans. *La Revue*
16
17 642 *De Gériatrie*, 36(9), 645–654.
18
19 643 [29] Reitan. R.M. (1958). Validity of the Trail Making Test as an Indicator of Organic Brain Damage, 8(3),
20
21 644 271–276. <https://doi.org/https://doi.org/10.2466/pms.1958.8.3.271>
22
23 645 [30] Erdodi, L.A., Abeare, C.A., Lichtenstein, J.D., Tyson, B.T., Kucharski, B., Zuccato, B.G., & Roth, R.M.
24
25 646 (2017). Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) processing speed scores as
26
27 647 measures of noncredible responding: The third generation of embedded performance validity
28
29 648 indicators. *Psychological Assessment*, 29(2), 148-157.
30
31 649 <https://doi.org/http://dx.doi.org/10.1037/pas0000319>
32
33 650 [31] Kalafat, M., Hugonot-Diener, L., & Poitrenaud, J. (2003). French standardization of the mini mental
34
35 651 state (MMS), greco's version. *Revue de neuropsychologie*, 13(2), 209-236.
36
37 652 [32] Yesavage, J., Brink, T., Rose, T., Lum, o, Huang, V., Adey, M., & Leirer, V. (1982). Development and
38
39 653 validation of a geriatric
40
41 654 depression screening scale: a preliminary report. *Journal Of Psychiatric Research*, 17(1), 35–49.
42
43 655 [33] Thomas-Anterion, C., Ribas, C., Honore-Masson, S., Berne, G., Ruel, J.H., & Laurent, B. (2003). Le
44
45 656 Questionnaire de Plainte Cognitive (QPC) : Un outil de recherche de plainte suspecte d'évoquer une
46
47 657 Maladie d'Alzheimer ? *L'année Gerontologique*, 17, 56–65.
48
49 658 [34] Lawton, M. P., & Brody, E. M. (1970). Assessment Of Older People: Self Maintaining And
50
51 659 Instrumental Activities For Daily Living. *Nursing Research*, 19(3), 278.
52
53 660 [35] Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh
54
55 661 Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry*
56
57 662 *Research*, 28(2), 193–213.
58
59 663 [36] Ware, J. E., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction
60
61 664 of scales and preliminary tests of reliability and validity. *Medical Care*, 34(3), 220. Retrieved
62
63 665 from https://journals.lww.com/lwwmedicalcare/Abstract/1996/03000/A_12_Item_Short_Form_Health_Survey_Construction.3.aspx <http://dx.doi.org/10.1590/S1807-59322011000800015>
64
65 666 [37] Vallerand, R. J., & O'connor, B. P. (1991). Construction et Validation de l'Échelle de Motivation
66
67 667 pour les Personnes Âgées (Empa). *International Journal of Psychology*, 26(2), 219–240.
68
69 668 <https://doi.org/10.1080/00207599108247888>
70

- 1
2
3 670 [38] Amieva, H., Lafont, S., Auriacombe, S., Le Carret, N., Dartigues, J. F., Orgogozo, J. M., & Colette, F.
4 671 (2002). Inhibitory breakdown and dementia of the Alzheimer type: a general phenomenon?. *Journal*
5 672 *of clinical and experimental neuropsychology*, 24(4), 503–516.
6 673 <https://doi.org/10.1076/jcen.24.4.503.1034>
7
8 674 [39] Friedman, N. P., Miyake, A., & Young, Susan E. DeFries, John C. Corley, Robin P. Hewitt, John K.
9 675 (2008). Individual differences in executive functions are almost entirely genetic in origin. *Journal of*
10 676 *Experimental Psychology*, 137(2), 201–225. [https://doi.org/http://dx.doi.org/10.1037/0096-](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
11 677 [3445.137.2.201](https://doi.org/http://dx.doi.org/10.1037/0096-3445.137.2.201)
12
13 678 [40] Barrouillet, P., Bernardin, S., & Camos, V. (2004). Time constraints and resource sharing in adults'
14 679 working memory spans. *Journal of Experimental Psychology. General*, 133(1), 83–100.
15 680 <https://doi.org/10.1037/0096-3445.133.1.83>
16
17 681 [41] Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., & Lyketsos, C. (2010).
18 682 Management of behavioral problems in Alzheimer's disease. *International Psychogeriatrics*, 22(3),
19 683 346–372. <https://doi.org/10.1017/S1041610209991505>
20
21 684 [42] Choi, J., & Twamley, E. W. (2013). Cognitive Rehabilitation Therapies for Alzheimer's Disease: A
22 685 Review of Methods to Improve Treatment Engagement and Self-Efficacy. *Neuropsychology Review*,
23 686 23(1), 48–62. <https://doi.org/10.1007/s11065-013-9227-4>
24
25 687 [43] Vianin, P., Urben, S., Magistretti, P., Marquet, P., Fornari, E., & Jaugey, L. (2014). Increased
26 688 activation in Broca's area after cognitive remediation in schizophrenia. *Psychiatry Research: Neuroimaging*, 221(3), 204–209. <https://doi.org/10.1016/j.psychresns.2014.01.004>
27
28 689 [44] Demily, C., Rigard, C., Peyroux, E., Chesnoy-Servanin, G., Morel, A., & Franck, N. (2016). «Cognitus
29 690 & Moi»: A Computer-Based Cognitive Remediation Program for Children with Intellectual Disability.
30 691 *Frontiers in Psychiatry*, 7. <https://doi.org/10.3389/fpsy.2016.00010>
31
32 692 [45] Bowie, C. R., Gupta, M., Holshausen, K., Jokic, R., Best, M., & Milev, R. (2013). Cognitive
33 693 Remediation for Treatment-Resistant Depression: Effects on Cognition and Functioning and the Role
34 694 of Online Homework. *Journal of Nervous & Mental Disease*, 201(8), 680–685.
35 695 <https://doi.org/10.1097/NMD.0b013e31829c5030>
36
37 696 [46] Bobillier Chaumon, M.-E., Michel, C., Tarpin Bernard, F., & Croisile, B. (2014). Can ICT improve the
38 697 quality of life of older adults adults living in residential home care units? From actual impacts to hidden
39 698 artefacts. *Behaviour & Information Technology*, 33(6), 574–590.
40 699 <https://doi.org/10.1080/0144929X.2013.832382>
41
42 700 [47] Joubert, C., & Chainay, H. (2019). Effects of Cognitive and Aerobic training on Working Memory
43 701 and Executive Function in Aging, a Pseudo-Randomized Trial: Pilot Study. *Journal of Aging Research*
44 702 *and Healthcare*, 2(3), 46–70. <https://doi.org/10.14302/issn.2474-7785.jarh-18-2458>
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 704 [48] Franck, N. (2013). Clinique de la schizophrénie. *EMC - Psychiatrie*, 10(1), 1–16.
4
5 705 [https://doi.org/10.1016/S0246-1072\(12\)59577-5](https://doi.org/10.1016/S0246-1072(12)59577-5)
6
7 706 [49] Sherman, D.S., Mauster, J., Nuno, M., & Sherzai, D. (2017). The efficiency of Cognitive Intervention
8 707 in Mild Cognitive Impairment (MCI): a meta-analysis of outcomes on neuropsychological measures.
9
10 708 *Neuropsychological Review*, 27, 440-484. <https://doi.org/10.1007/s11065-017-9363-3>.
11
12 709 [50] Kallio, E-L. (2019). *Effects of cognitive training on cognition and quality of life in older adults with*
13 710 *dementia*. Helsinki : [E.-L. Kallio].
14
15 711
16 712

For peer review only




Figure 1: illustrating on the time axis the evolution of the experiment with the facts marked on a weekly basis trainings take place between the 2nd and the 17th week for the 3 training groups simultaneously. Note: V = Visit; W = Week; D = Day; T = Time of assessment; REG = regular group; HFG = high frequency group; MHG = moderate frequency group.

321x118mm (72 x 72 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Administrative information | | | |
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 1 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 7 |
| Protocol version | #3 | Date and version identifier | 5 |
| Funding | #4 | Sources and types of financial, material, and other support | 19 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 1;19 |

| | | | | |
|----|---------------------------|---------------------|--|-----|
| 1 | Roles and | #5b | Name and contact information for the trial sponsor | n/a |
| 2 | responsibilities: | | | |
| 3 | sponsor contact | | | |
| 4 | information | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | n/a |
| 9 | responsibilities: | | collection, management, analysis, and interpretation of data; | |
| 10 | sponsor and funder | | writing of the report; and the decision to submit the report for | |
| 11 | | | publication, including whether they will have ultimate authority | |
| 12 | | | over any of these activities | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating centre, | 11 |
| 17 | responsibilities: | | steering committee, endpoint adjudication committee, data | |
| 18 | committees | | management team, and other individuals or groups overseeing the | |
| 19 | | | trial, if applicable (see Item 21a for data monitoring committee) | |
| 20 | | | | |
| 21 | | | | |
| 22 | | | | |
| 23 | Introduction | | | |
| 24 | | | | |
| 25 | Background and | #6a | Description of research question and justification for undertaking | 4 |
| 26 | rationale | | the trial, including summary of relevant studies (published and | |
| 27 | | | unpublished) examining benefits and harms for each intervention | |
| 28 | | | | |
| 29 | | | | |
| 30 | Background and | #6b | Explanation for choice of comparators | n/a |
| 31 | rationale: choice of | | | |
| 32 | comparators | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | Objectives | #7 | Specific objectives or hypotheses | 4 |
| 37 | | | | |
| 38 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 5 |
| 39 | | | group, crossover, factorial, single group), allocation ratio, and | |
| 40 | | | framework (eg, superiority, equivalence, non-inferiority, | |
| 41 | | | exploratory) | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | Methods: | | | |
| 46 | Participants, | | | |
| 47 | interventions, and | | | |
| 48 | outcomes | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Study setting | #9 | Description of study settings (eg, community clinic, academic | 5 |
| 52 | | | hospital) and list of countries where data will be collected. | |
| 53 | | | Reference to where list of study sites can be obtained | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 6 |
| 58 | | | eligibility criteria for study centres and individuals who will | |
| 59 | | | | |
| 60 | | | | |

| | | | |
|----|------------------------------|--|-----|
| | | perform the interventions (eg, surgeons, psychotherapists) | |
| 1 | | | |
| 2 | Interventions: | #11a Interventions for each group with sufficient detail to allow | 10 |
| 3 | description | replication, including how and when they will be administered | |
| 4 | | | |
| 5 | Interventions: | #11b Criteria for discontinuing or modifying allocated interventions for a | n/a |
| 6 | modifications | given trial participant (eg, drug dose change in response to harms, | |
| 7 | | participant request, or improving / worsening disease) | |
| 8 | | | |
| 9 | Interventions: | #11c Strategies to improve adherence to intervention protocols, and any | n/a |
| 10 | adherence | procedures for monitoring adherence (eg, drug tablet return; | |
| 11 | | laboratory tests) | |
| 12 | Interventions: | #11d Relevant concomitant care and interventions that are permitted or | 6 |
| 13 | concomitant care | prohibited during the trial | |
| 14 | | | |
| 15 | Outcomes | #12 Primary, secondary, and other outcomes, including the specific | 7-9 |
| 16 | | measurement variable (eg, systolic blood pressure), analysis metric | |
| 17 | | (eg, change from baseline, final value, time to event), method of | |
| 18 | | aggregation (eg, median, proportion), and time point for each | |
| 19 | | outcome. Explanation of the clinical relevance of chosen efficacy | |
| 20 | | and harm outcomes is strongly recommended | |
| 21 | Participant timeline | #13 Time schedule of enrolment, interventions (including any run-ins | 7 |
| 22 | | and washouts), assessments, and visits for participants. A | |
| 23 | | schematic diagram is highly recommended (see Figure) | |
| 24 | | | |
| 25 | Sample size | #14 Estimated number of participants needed to achieve study | 12 |
| 26 | | objectives and how it was determined, including clinical and | |
| 27 | | statistical assumptions supporting any sample size calculations | |
| 28 | | | |
| 29 | Recruitment | #15 Strategies for achieving adequate participant enrolment to reach | 5 |
| 30 | | target sample size | |
| 31 | | | |
| 32 | | | |
| 33 | | | |
| 34 | | | |
| 35 | | | |
| 36 | | | |
| 37 | | | |
| 38 | | | |
| 39 | | | |
| 40 | | | |
| 41 | | | |
| 42 | | | |
| 43 | | | |
| 44 | | | |
| 45 | Methods: Assignment | | |
| 46 | of interventions (for | | |
| 47 | controlled trials) | | |
| 48 | | | |
| 49 | | | |
| 50 | Allocation: sequence | #16a Method of generating the allocation sequence (eg, computer- | n/a |
| 51 | generation | generated random numbers), and list of any factors for | |
| 52 | | stratification. To reduce predictability of a random sequence, | |
| 53 | | details of any planned restriction (eg, blocking) should be provided | |
| 54 | | in a separate document that is unavailable to those who enrol | |
| 55 | | participants or assign interventions | |
| 56 | | | |
| 57 | | | |
| 58 | | | |
| 59 | | | |
| 60 | | | |

| | | | | |
|----|------------------------|----------------------|--|---------|
| 1 | Allocation concealment | #16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | n/a |
| 2 | mechanism | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | 5-6 |
| 9 | implementation | | | |
| 10 | | | | |
| 11 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | n/a |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | n/a |
| 18 | emergency unblinding | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Methods: Data | | | |
| 23 | collection, | | | |
| 24 | management, and | | | |
| 25 | analysis | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | 7-9; 11 |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | Data collection plan: | #18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | n/a |
| 40 | retention | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | Data management | #19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | 12 |
| 45 | | | | |
| 46 | | | | |
| 47 | | | | |
| 48 | | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | 13 |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | n/a |
| 57 | analyses | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------------|----------------------|---|-----|
| 1 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non- | n/a |
| 2 | population and missing | | adherence (eg, as randomised analysis), and any statistical methods | |
| 3 | data | | to handle missing data (eg, multiple imputation) | |
| 4 | | | | |
| 5 | | | | |
| 6 | Methods: Monitoring | | | |
| 7 | | | | |
| 8 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary of its | 11 |
| 9 | formal committee | | role and reporting structure; statement of whether it is independent | |
| 10 | | | from the sponsor and competing interests; and reference to where | |
| 11 | | | further details about its charter can be found, if not in the protocol. | |
| 12 | | | Alternatively, an explanation of why a DMC is not needed | |
| 13 | | | | |
| 14 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 13 |
| 15 | interim analysis | | including who will have access to these interim results and make | |
| 16 | | | the final decision to terminate the trial | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | | | | |
| 22 | Harms | #22 | Plans for collecting, assessing, reporting, and managing solicited | 10 |
| 23 | | | and spontaneously reported adverse events and other unintended | |
| 24 | | | effects of trial interventions or trial conduct | |
| 25 | | | | |
| 26 | | | | |
| 27 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, and | 11 |
| 28 | | | whether the process will be independent from investigators and the | |
| 29 | | | sponsor | |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | Ethics and | | | |
| 34 | dissemination | | | |
| 35 | | | | |
| 36 | Research ethics | #24 | Plans for seeking research ethics committee / institutional review | 13 |
| 37 | approval | | board (REC / IRB) approval | |
| 38 | | | | |
| 39 | | | | |
| 40 | Protocol amendments | #25 | Plans for communicating important protocol modifications (eg, | 13 |
| 41 | | | changes to eligibility criteria, outcomes, analyses) to relevant | |
| 42 | | | parties (eg, investigators, REC / IRBs, trial participants, trial | |
| 43 | | | registries, journals, regulators) | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |
| 47 | Consent or assent | #26a | Who will obtain informed consent or assent from potential trial | 6 |
| 48 | | | participants or authorised surrogates, and how (see Item 32) | |
| 49 | | | | |
| 50 | | | | |
| 51 | Consent or assent: | #26b | Additional consent provisions for collection and use of participant | n/a |
| 52 | ancillary studies | | data and biological specimens in ancillary studies, if applicable | |
| 53 | | | | |
| 54 | | | | |
| 55 | Confidentiality | #27 | How personal information about potential and enrolled participants | 6 |
| 56 | | | will be collected, shared, and maintained in order to protect | |
| 57 | | | confidentiality before, during, and after the trial | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|---|----------------------|---|-------|
| 1 | Declaration of interests | #28 | Financial and other competing interests for principal investigators for the overall trial and each study site | 19 |
| 2 | | | | |
| 3 | | | | |
| 4 | Data access | #29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | 12 |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Ancillary and post trial care | #30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | n/a |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | Dissemination policy: trial results | #31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | 13-14 |
| 15 | | | | |
| 16 | | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | | | | |
| 21 | Dissemination policy: authorship | #31b | Authorship eligibility guidelines and any intended use of professional writers | 19 |
| 22 | | | | |
| 23 | | | | |
| 24 | Dissemination policy: reproducible research | #31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | n/a |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Appendices | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Informed consent materials | #32 | Model consent form and other related documentation given to participants and authorised surrogates | n/a |
| 32 | | | | |
| 33 | | | | |
| 34 | Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | n/a |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |

40 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons
 41 Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a
 42 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59